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1. Introduction 
Chronic kidney disease (CKD) is a worldwide public health issue. In the United States there 
is a rising incidence and prevalence of kidney failure with poor outcomes and high cost. 
Most chronic nephropathies are characterized by a progressive course that leads, at a 
variable rate, to loss of kidney function and the need for renal replacement therapy. The 
progression of CKD typically moves through phases from initial diminution of renal reserve 
to mild, moderate and severe reductions in glomerular filtration rate (GFR), to end-stage 
renal disease (ESRD). There is growing evidence that some of the adverse outcomes of CKD 
can be prevented or delayed by preventive measures, early detection and treatment. 
2. Definitions and classification 
The definition and classification of CKD may help identify affected patients, possibly 
resulting in the early institution of effective therapy. To achieve this goal, guidelines were 
proposed from the National Kidney Foundation of the United States through its Kidney 
Disease Outcomes Quality Initiative (K/DOQI) program (National kidney Foundation 
[NKF], 2002). These guidelines have been reviewed and accepted internationally (Levey et 
al., 2005; Uhlig et al., 2005; Levin et al., 2008). 
The K/DOQI working group defined CKD in adults as: 
• Evidence of structural or functional kidney abnormalities (abnormal urinalysis, imaging 
studies, or histology) that persist for at least three months, with or without a decreased 
GFR. The most common manifestation of kidney damage is persistent albuminuria, 
including microalbuminuria. 
 OR 
• Decreased GFR (as defined by a GFR of less than 60 ml/min per 1.73 m2), with or 
without evidence of kidney damage. 
Based upon these definitions, the following is the recommended classification of CKD by 
stage and the estimated prevalence within the United States of each stage, as determined by 
a National Health and Nutrition Examination Survey (NHANES) performed in 1999 to 2004 
(KDOQI, 2002; Coresh et al., 2003; Levey et al., 2003; Coresh et al., 2005; MMWR, 2007; 
Coresh et al, 2007). 
• Stage 1 disease is defined by a normal GFR (greater than 90 ml/min per 1.73 m2) and 
persistent albuminuria (1.8 percent of the total United States population) 
• Stage 2 disease is a GFR between 60 to 89 ml/min per 1.73 m2 and persistent 
albuminuria (3.2 percent) 
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• Stage 3 disease is a GFR between 30 and 59 ml/min per 1.73 m2 (7.7 percent) 
• Stage 4 disease is a GFR between 15 and 29 ml/min per 1.73 m2 (0.21 percent) 
• Stage 5 disease is a GFR of less than 15 ml/min per 1.73 m2 or ESRD (2.4 percent for 
stages.) 
2.1 Estimation of glomerular filtration rate (GFR) 
Patients with kidney disease may have a variety of different clinical presentations. Some 
have symptoms that are directly referable to the kidney (gross hematuria,or flank pain), or 
to extrarenal symptoms (edema, hypertension, signs of uremia). Many patients, however, 
are asymptomatic and are noted during routine examination to have an elevated serum 
creatinine concentration, or an abnormal urinalysis. 
Once kidney disease is discovered, the presence or degree of kidney dysfunction and 
rapidity of progression are assessed, and the underlying disorder is diagnosed. Although 
the history and physical examination can be helpful, the most useful information is initially 
obtained from estimation of the GFR and examination of the urinary sediment. 
Estimation of the GFR is used clinically to assess the degree of kidney impairment and to 
follow the course of the disease. However, the GFR provides no information on the cause of 
the kidney disease. This is achieved by the urinalysis, measurement of urinary protein 
excretion, and, if necessary, radiologic studies and/or kidney biopsy. 
2.2 Laboratory measurement for diagnosis of CKD 
2.2.1 For all patients at increased risk for CKD 
• Serum creatinine to estimate GFR; 
• Albumin-to-creatinine or protein-to-creatinine ratio in a first-morning or random 
untimed ‘spot’ urine specimen; 
• Examination of the urine sediment or dipstick for red bloodcells and white blood cells. 
2.2.2 For patients found to have CKD 
• Imaging of the kidneys, usually by ultrasound; 
• Serum electrolytes (sodium, potassium, chloride and bicarbonate) 
2.2.3 Estimation of GFR 
Once kidney disease is discovered, the presence or degree of kidney dysfunction and rapidity 
of progression are assessed, and the underlying disorder is diagnosed. Early identification of 
patients with CKD would allow treatment that could slow the progression to ESRD, improve 
clinical outcomes, and constrain the growth of costs in the ESRD program. Although the 
history and physical examination can be helpful, the most useful information is initially 
obtained from estimation of the GFR and examination of the urinary sediment. 
Estimation of the GFR is used clinically to assess the degree of kidney impairment and to 
follow the course of the disease. However, the GFR provides no information on the cause of 
the kidney disease. This is achieved by the urinalysis, measurement of urinary protein 
excretion, and, if necessary, radiologic studies and/or kidney biopsy. 
The GFR is equal to the sum of the filtration rates in all of the functioning nephrons, thus, 
estimation of the GFR gives an approximate measure of the number of functioning 
nephrons. GFR cannot be measured directly. Instead it is measured as the urinary clearance 
of an ideal filtration marker. 
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The most reliable assessment of GFR is based on the measurement of kidney clearance of a 
filtration marker such as Inulin which is a physiologically inert substance that is freely 
filtered at the glomerulus, and is neither secreted, reabsorbed, synthesized, nor metabolized 
by the kidney (Rahn et al., 1999). Thus, the amount of inulin filtered at the glomerulus is 
equal to the amount excreted in the urine, which can be measured. Inulin, however, is in 
short supply, expensive, and difficult to assay and is not suitable for routine clinical practice, 
and is cumbersome even for clinical research. Furthermore, the classic protocol for 
measuring inulin clearance requires a continuous intravenous infusion, multiple blood 
samples, and bladder catheterization. 
Various less cumbersome methods for measuring clearance are available: using alternative 
filtration markers (such as radioactive or non-radioactive iothalamate, iohexol, DTPA, or 
EDTA), bolus administration of the marker (subcutaneous or intravenous), spontaneous 
bladder emptying, and plasma clearance (Rahn et al., 1999; Levey, 1990; Brandstrom et al., 
1998). While these methods are simpler, all have disadvantages that limit their application in 
clinical practice and affect the interpretation of research studies. 
In the United States, the most common methods utilized to estimate the GFR are the serum 
creatinine concentration, the creatinine clearance, or estimation equations based upon the 
serum creatinine: such as the Cockcroft-Gault equation and Modification of Diet in Renal 
Disease (MDRD) Study equations.  
The K/DOQI guidelines classified patients by CKD stage, which is defined in part by the 
estimated GFR (table 1). The GFR should be estimated from the MDRD and Cockcroft-Gault 
equations, which take into account the serum creatinine concentration, and some or all of 
the following variables: age, gender, race, and body size.  
The Cockcroft-Gault formula estimates creatinine clearance in milliliters per minute, and the 
MDRD  equation estimates GFR in milliliters per minute per 1.73 m2, and this difference 
should be kept in mind when comparing their outputs. However, the estimation equations 
have not been validated, and may be less accurate, in some populations. These include 
individuals with high, normal, or near-normal renal function, children, certain ethnic 
groups, pregnant women, and those with unusual muscle mass, body habitus, and weight 
(eg, morbid obesity or malnourished). Some, therefore, recommend measuring the 
creatinine clearance to estimate the GFR in these patients with stable renal function. Most 
patients with CKD stages 3 to 5 progress relentlessly to ESRD. A straight-line relationship is 
often found between the reciprocal of serum creatinine (1/SCr) values or the estimated GFR 
and time. The rate of progression of CKD varies according to the underlying nephropathy 
and how the kidney responds to injury. 
Because of the problems with changes in creatinine production and secretion, other 
endogenous compounds have been evaluated in an effort to provide a more accurate 
estimation of GFR including symmetric dimethylarginine (Kielstein et al., 2006) and cystatin C. 
Perhaps the best studied and most promising is cystatin C, a low molecular weight protein, 
that is a member of the cystatin superfamily of cysteine protease inhibitors. Cystatin C is 
filtered at the glomerulus and not reabsorbed. However, it is metabolized in the tubules, 
which prevents use of cystatin C to directly measure clearance. 
Cystatin C is thought to be produced by all nucleated cells; its rate of production has been 
thought to be relatively constant, and not affected by changes in diet, although this is not 
proven. Cystatin C has been purported to be unaffected by gender, age or muscle mass. 
However, higher cystatin C levels have now been associated with male gender, greater 
height and weight, and higher lean body mass (Knight et al., 2004; Groesbeck et al., 2008; 
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Macdonald et al., 2006). Cystatin C levels increase sharply with age (Knight et al., 2004). 
Analysis of a sub-sample of 7596 participants drawn from National Health and Nutrition 
Examination Survey III (NHANES III) revealed that more than 50 percent of individuals 
over age 80 have an elevated cystatin C level, and non-Hispanic whites and males have 
higher levels of cystatin C (Kottgen et al., 2008). These data were not adjusted for GFR; 
therefore, it is unclear whether they are related to different levels of kidney function among 
the populations, or difference in the non-GFR determinants of cystatin C. In addition, 
cystatin is affected by hyper- and hypothyroidism, and has been correlated with markers of 
inflammation (C-reactive protein), body size (in particular fat mass), and diabetes (Manetti 
et al., 2005; Stevens et al., 2009). Together, these data suggest that levels of cystatin C are 
affected by factors other than GFR. 
Although reference ranges have been reported, there is no current standard for serum 
cystatin C measurements (Shlipak et al., 2005; Mussap & Plebani, 2004). In addition, testing 
for cystatin C is only available in a limited number of laboratories. 
The serum cystatin C concentration may correlate more closely with the GFR than the serum 
creatinine concentration (Newman et al., 1995; Coll et al., 2000; Fliser & Ritz, 2001; Mussap et 
al., 2002; Ahlstrom et al., 2004; Hoek et al., 2003; Dharnidharka et al., 2002; Poge et al., 2006; 
Stevens et al., 2008). In multiple studies, serum cystatin C was more sensitive in identifying 
mild reductions in kidney function than serum creatinine (Coll et al., 2000; Hoek et al., 2003; 
Dharnidharka et al., 2002). Using the clearance of radioactive iothalamate as the gold standard, 
serum cystatin C levels began increasing at GFR levels of approximately 90 mL/min per 1.73 
m2, while the serum creatinine only increased when the GFR was approximately 70 mL/min 
per 1.73 m2. Whether cystatin C correlates better with GFR than serum creatinine in patients 
with diabetic nephropathy is unclear (Oddoze et al., 2001; Perkins et al., 2005). 
Estimation equations based on serum cystatin C have also been formulated (Grubb et al., 
2005; Sjostrom et al., 2005; Grubb et al., 2005). It has been proposed that cystatin C-based 
equations would be more accurate in populations with lower creatinine production, such as 
the elderly, children, renal transplant recipients, or patients with cirrhosis (White et al., 2005; 
Poge et al., 2006). In one study of over 3000 patients with known CKD, an equation for the 
estimated GFR based upon cystatin C was nearly as accurate as GFR estimated from the 
serum creatinine adjusted for age, sex, and race when compared to GFR measured by 
iothalamate clearance (Stevens et al., 2008). The addition of age, sex and race to cystatin C 
reduced bias in some subgroups defined by these variables, and an equation that uses both 
serum creatinine and cystatin C with age, sex and race was better than equations that used 
only one of these markers. 
Steroid use may affect cystatin C levels, therefore, limiting its use in transplant recipients. 
As an example, for the same level of cystatin C, measured GFR was 19 percent higher in 
transplant recipients than in patients with native kidney disease. 
Although cystatin C appears to be more accurate for the assessment of GFR than serum 
creatinine in certain populations, whether measurement of cystatin C levels will improve 
patient care is at present unknown [Deinum & Derkx, 2000). 
2.3 Markers of kidney damage 
Markers of kidney damage include proteinuria, hematuria, and other abnormalities of the 
urinary sediment, and radiologic evidence of damage. The most common cause of CKD in 
adults are diabetes and hypertension, and, therefore, the most common marker  for kidney 
damage is increased excretion of protein, and specifically of albumin. Measurement of 
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protein excretion is useful in a variety of clinical settings, particularly to establish the 
diagnosis and to follow the course of glomerular disease.  
In normal subjects, low molecular weight proteins and small amounts of albumin are 
filtered. The actual amount of albumin filtered each day in humans is controversial. The 
majority view is that no more than about 2 to 4 g of albumin per day are filtered normally, 
but some investigators claim that as much as 200 g of albumin are filtered each day (with the 
bulk of this filtered albumin "reclaimed" in the early proximal tubule) (Russo et al., 2007). 
The filtered proteins enter the proximal tubule where they are almost completely reabsorbed 
and then catabolized by the proximal tubular cells. Some of the catabolized proteins 
(including albumin) are excreted as peptides in the urine. These are not detected by dipstick 
or the immuno-nephelometric albumin-specific assays, but are detected by chromatographic 
assays. The net result is the normal daily protein excretion of less than 150 mg (usually 40 to 
80 mg), of which approximately about 4 to 7 mg is intact, immuno-reactive albumin. 
Previously, abnormal proteinuria was generally defined as the excretion of more than 150 
mg of protein per day. However, it is now clear that early renal disease is reflected by lesser 
degrees of proteinuria, particularly increased amounts of albuminuria. 
The normal rate of albumin excretion is less than 20 mg/day (15 μg/min); the rate is about 4 
to 7 mg/day in healthy young adults and increases with age and with an increase in body 
weight. Persistent albumin excretion between 30 and 300 mg/day (20 to 200 µg/min) is 
called microalbuminuria. In patients with diabetes, this is usually indicative of incipient 
diabetic nephropathy (unless there is some co-existent renal disease). In non-diabetics, the 
presence of microalbuminuria is associated with cardiovascular disease.Values above 300 
mg/day (200 µg/min) are considered to represent overt proteinuria or macroalbuminuria, 
the level at which the standard dipstick becomes positive. At this level, practically all 
protein in the urine consists of albumin.  
The standard urinary dipstick measures albumin concentration via a colorimetric reaction 
between albumin and tetrabromophenol blue producing different shades of green according 
to the concentration of albumin in the sample 
• Negative 
• Trace — between 15 and 30 mg/dl 
• 1+ — between 30 and 100 mg/dl 
• 2+ — between 100 and 300 mg/dl 
• 3+ — between 300 and 1000 mg/dl 
• 4+ — >1000 mg/dl 
The urine dipstick is, therefore, not very accurate in assessing the severity of proteinuria 
since the protein concentration is a function of urine volume as well as the quantity of 
protein present. As an example, suppose a patient excretes 500 mg of protein per day. If the 
urine volume is two liters, the protein concentration will be 25 mg/dl, resulting in a trace to 
1+ findings on the dipstick. However, if the urine volume is only 500 ml, the protein 
concentration will be 100 mg/dl and the dipstick will read 2+. 
The urine dipstick is also a relatively insensitive marker for initial increases in protein 
excretion, not generally becoming positive until protein excretion exceeds 300 to 500 mg/day. 
Limited data suggest that the combination of specific gravity plus dipstick proteinuria may 
significantly improve the ability to detect proteinuria (Constantiner et al., 2005). 
The dipstick may also be insufficiently sensitive in multiple myeloma. Given that the dipstick 
primarily detects urinary albumin, it may be negative in patients with multiple myeloma who 
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may excrete relatively large amounts of monoclonal immunoglobulin light chains. In contrast, 
testing the urine with sulfosalicylic acid will detect all proteins, as evidenced by the degree of 
turbidity (Rose, 1987). As a result, any patient with unexplained renal failure, a benign urine 
sediment, and a negative dipstick for protein should have the urine tested with sulfosalicylic 
acid. A positive finding suggests the presence of non-albumin proteins in the urine, which in 
adults usually represents immunoglobulin light chains.  
The accurate measurement of protein excretion in the urine can be performed by several 
different techniques. The gold standard for measurement of protein excretion is a 24 hour 
urine collection, with the normal value being less than 150 mg/day. However, an adequate 
collection must be ensured. This is cumbersome for patients and physicians; thus, 
measurement on random specimens has become an accepted alternative method. 
The preferred method of measuring urinary protein excretion in patients with proteinuria is 
either the total protein-to-creatinine ratio or albumin-to-creatinine ratio for 
microalbuminuria on a random urine specimen (Eknoyan et al., 2003; KDOQI, 2002). 
These ratios on a random urine specimen correlate fairly closely with daily protein excretion 
in g/1.73 m2 of body surface area (Ginsberg et al., 1983; Schwab et al., 1987; Abitbol et al., 
1990; Steinhauslin & Wauters, 1995; Chitalia et al., 2001; Zelmanovitz et al., 1997; Bakker,  
1999). Thus, a ratio of 4.9 (as with respective urinary protein and creatinine concentrations 
of 210 and 43 mg/dl) represents daily protein excretion of approximately 4.9 g/1.73 m2. 
The accuracy of the ratio is diminished when creatinine excretion is either markedly 
increased in a muscular man (the ratio will underestimate proteinuria) or markedly reduced 
in a cachectic patient (the ratio will overestimate proteinuria). 
Because of this markedly increased convenience, the total protein-to-creatinine ratio or 
albumin-to-creatinine ratio are preferred to the 24 hour urine collection for quantitative 
measurement of significant urinary protein. First morning specimens are preferred, but 
random daytime specimens are acceptable if first morning specimens are not available 
(Witte et al., 2009). Specimens obtained in the evening or overnight appear to be least 
accurate. 
The range of the urinary albumin-to-creatinine ratio with microalbuminuria varies by 
gender, being 20 to 200 mg/g and 30 to 300 mg/g for males and females, respectively. This 
is a result of the higher muscle mass observed in males. 
Hematuria or pyuria originating in the renal parenchyma, glycosuria in the absence of 
hyperglycemia, and abnormal radiologic or pathologic studies are others diagnostic criteria 
for CKD. 
3. Natural history of CKD 
The kidney is able to adapt to damage by increasing the filtration rate in the remaining 
normal nephrons, a process called adaptive hyperfiltration. As a result, the patient with 
mild renal insufficiency often has a normal or near-normal serum creatinine concentration. 
Additional homeostatic mechanisms (most frequently occurring within the renal tubules) 
permit the serum concentrations of sodium, potassium, calcium, and phosphorous and the 
total body water to also remain within the normal range, particularly among those with 
mild to moderate renal failure. Adaptive hyperfiltration, although initially beneficial, 
appears to result in long-term damage to the glomeruli of the remaining nephrons, which is 
manifested by proteinuria and progressive renal insufficiency. This process appears to be 
responsible for the development of renal failure among those in whom the original illness is 
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either inactive or cured (Abboud & Henrich, 2010). The institution of measures to help 
prevent this process, such as antihypertensive therapy with an angiotensin converting 
enzyme inhibitor or an angiotensin II receptor blocker, may slow progressive disease and 
even preserve renal function. If these modalities are effective, the benefit is likely to be 
greatest if begun before a great deal of irreversible scarring has occurred.  
Not all individuals have progressive loss of kidney function. Some studies show a high rate 
of progression, while others report relatively stable disease (Sarnak et al., 2005; Eriksen & 
Ingebretsen, 2006; Hallan et al., 2006). The rate of progression of CKD from one major stage 
to another varies based upon the underlying disease, presence or absence of comorbid 
conditions, treatments, socioeconomic status, individual genetics, ethnicity, and other 
factors. 
Using epidemiologic data, general estimates for the rate of transition from a GFR between 15 
to 60 ml/min per 1.73 m2 to end stage disease may be approximately 1.5 percent per year, 
while the rate of transition from a GFR above 60 to below 60 ml/min per 1.73 m2 may be 
approximately 0.5 percent per year (Hsu et al., 2004; Fox et al., 2004). 
Historically, rate of decline in GFR of patients with diabetic nephropathy (DN) has been 
among the fastest, averaging about 10 ml/min/year. Control of systemic hypertension 
slows the rate of GFR decline to 5ml/min/year. In non-diabetic nephropathy, the rate of 
progression of CKD was 2.5 times faster in patients with chronic glumerulonephritis than in 
those with chronic interstitial nephritis, and 1.5 times faster than in those with hypertensive 
nephrosclerosis. Polycystic kidney disease (PKD) and impaired renal function may also 
have a faster rate of progression compared to those with other nephropathies. 
4. Prevalence of chronic kidney disease 
The prevalence of CKD has been evaluated based on serum creatinine concentrations  and 
microalbuminuria in the following population studies from the United States, as well as 
some other countries. 
In the Third National Health and Nutrition Examination Survey (NHANES III), serum 
creatinine concentration was obtained in a sample of 18,723 individuals aged 12 years and 
older between 1988 and 1994 (Jones et al., 1998). The prevalence of a serum creatinine level 
at or above 1.5, 1.7, and 2.0 mg/dl was 5.0, 1.9, and 0.6 percent for men, respectively, and 
1.6, 0.7, and 0.3 percent for women. 
By extrapolating the results of the NHANES III to the 1990 US Census population, it was 
estimated that the number of people with serum creatinine at or above 1.5, 1.7, and 2.0 
mg/dl is 6.2, 2.5, and 0.8 million, respectively. It should be noted, however, that only a 
single creatinine measurement per patient was used to estimate the prevalence of CKD, and 
that serum creatinine was available in only 31 percent of the potentially eligible sample. 
In a study of nearly 200,000 patients enrolled in a large health maintenance organization 
(HMO) in the southwestern US in 1997, the prevalence of at least one gender specific 
elevated serum creatinine (>1.2 mg/dl in women and >1.4 mg/dl in men) was 3.7 percent, 
and of at least two elevated serum creatinine levels separated by at least 90 days was 1.7 
percent (Nissenson et al., 2001). 
The prevalence estimates from this HMO study, as applied to United States Census data, led 
to the estimate of 9.1 million Americans in 1990 who had at least one elevated serum 
creatinine concentration, and 4.2 million Americans who had at least two elevated creatinine 
values separated by 90 days or greater. 
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The prevalence  of CKD in Norway was estimated from a population-based health survey of 
Nord-Trondelag County (HUNT II), which included 65,181 adults in 1995 through 1997 
(participation rate 70.4%) (Erikson & Ingebretsen, 2006). The primary analysis used gender-
specific cutoffs in estimating persistent albuminuria for CKD stages 1 and 2. Total CKD 
prevalence in Norway was 10.2% (SE 0.5): CKD stage 1 (GFR>90 ml/min per 1.73 m2 and 
albuminuria), 2.7% (SE 0.3); stage 2 (GFR 60 89 ml/min per 1.73 m2 and albuminuria), 3.2% 
(SE 0.4); stage 3 (GFR 30 to 59 ml/min per 1.73 m2, 4.2% (SE 0.1); and stage 4 (GFR 15 to 29 
ml/min per 1.73 m2, 0.2% (SE 0.01). 
Forty two percent of men and 44 percent of women over the age of 85 had an MDRD-
estimated GFR less than 60 ml/min per 1.73 m2 in the Nijmegen Biomedical Study, a 
population-based cross-sectional study conducted in the eastern part of the Netherlands. In 
a report from Taiwan, the prevalence of an estimated GFR <60 ml/min per 1.73 m2 was 7 % 
(Hsu et al., 2006). 
In a population-based survey from Pakistan, Kazmi et al have reported the prevalence of 
CKD stages 3 and 4 to be about 21 million (Kazmi et al., 2007). 
 
Stage Description GFR (ml/min/1.73m2) 
1 Kidney damage with normal GFR 90 or more 
2 Mildly deceased GFR 60 - 89 
3 Moderately decreased GFR 30 - 59 
4 Severely decreased GFR 15 - 29 
5 
Advanced kidney failure requiring 
dialysis/kidney transplant 
< 15 
Table 1. National Kidney Foundation K/DOQI Classification of Chronic Kidney Disease 
based on GFR levels. 
5. Screening for chronic kidney disease 
The NKF-K/DOQI guidelines for CKD, which have been reviewed and endorsed by  
the 2006 Kidney Disease Improving Global Outcomes (KDIGO) Controversies  
Conference, recommend that all individuals should be assessed as part of routine health 
examinations to determine whether they are at increased risk for developing CKD  
(KDOQI, 2002). 
Some data suggest, however, that screening the general population may decrease the 
incidence of ESRD resulting from glomerulonephritis. However, screening the general 
population is unlikely to be cost-effective. Screening for CKD among select patients who are 
at risk for development of CKD is justified because therapeutic interventions may slow or 
prevent the progression toward ESRD. Such patients include those with a history of 
diabetes, cardiovascular disease, hypertension, hyperlipidemia, obesity, metabolic 
syndrome, smoking, HIV or hepatitis C virus infection, and malignancy. A family history of 
CKD, age >60 years and treatment with potentially nephrotoxic drugs should also prompt 
screening for CKD.  Testing for CKD can be done with a urinalysis, a first morning or a 
random "spot" urine sample for albumin or protein and creatinine assessment, and a serum 
creatinine level. Depending upon the presence of particular risk factors, additional testing 
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such as renal ultrasonography may be required, such as in patients with a family history of 
polycystic kidney disease. Once the diagnosis is established and the cause and/or 
potentially reversible factors are identified and treated, CKD should be staged according to 
the classification proposed by the NKF-K/DOQI. 
6. Mechanisms of progression of chronic kidney disease 
Regardless of the nature of the underlying nephropathy, the progression of CKD is 
associated with the progressive sclerosis of glomeruli, tubulointerstitial fibrosis, and 
vascular sclerosis which can be initiated by endothelial, mesangial, or epithelial cell injury or 
damage. The kidney responds to injury by adaptive changes that lead to remodeling 
evolving towards either healing and functional recovery or scarring with loss of kidney 
function and progressive CKD. Healing is characterized by recovery of kidney function and 
structure. It occurs primarily in AKI when acutely damaged tubules recover from the initial 
insult and replace lost tubular cells to reconstitute the integrity of the tubules and to restore 
kidney function.  
On the other hand, most forms of chronic kidney damage, such as those induced by 
diabetes, hypertension, chronic glomerulonephritis, or chronic exposure to infections, 
evolve to progressive scarring with loss of function and CKD. Scarring is characterized by 
progressive loss of intrinsic renal cells and their replacement by fibrous tissue made of 
collagenous extracellular matrix.  
Within glomerular capillaries, endothelial cells are the first to be exposed to damage 
induced by hemodynamic, immunologic, or metabolic insults. Glomerular endothelial 
injury is associated with reduction or loss of their physiologic anticoagulant and anti-
inflammatory properties and the acquisition of procoagulant and inflammatory 
characteristics. 
Glomerular endothelial injury can induce proliferation, phenotype change (expression of 
adhesion molecules), release of vasoactive agents (endothelin, nitric oxide), infiltration of 
glomerular tufts by inflammatory cells and conversion to a prothrombotic state. Glomerular 
endothelial injury is characterized by proliferation, apoptosis, detachment, and 
(particularly) thrombosis. 
Mesangial cells are the glomerular capillary equivalent to the smooth muscle cells and in 
that capacity respond to injury in a similar fashion; death, transformation, proliferation, and 
migration as well as synthesis and deposition of extracellular matrix.  
The mesangial response to injury is characterized by alterations in cell cycle proteins that 
favor cell proliferation, phenotype change (to an actin positive myofibroblast), extracellular 
matrix production, and apoptosis. Many of these effects involve agonist interaction with 
specific receptors on the mesangial cell, including receptors for IgA, toll-like receptors, and 
transferrin receptors. Platelet derived growth factor (PDGF) appears to be the principal 
mediator of mesangial cell migration and proliferation in glomerular disease, an effect 
possibly magnified in hypoxic conditions. Receptors for PDGF are also upregulated. Further 
support for a role for PDGF is provided by a study that demonstrated prevention of renal 
scarring by antagonism of PDGF in an animal model of glomerulonephritis. 
Mesangial cell proliferation is associated with the increased expression of cyclin-dependent 
kinases and reduced expression of cyclin kinase inhibitors, such as P21 and P27. Mesangial 
cell proliferation is an essential precursor to subsequent mesangial matrix expansion and 
www.intechopen.com
 
Topics in Renal Biopsy and Pathology 
 
206 
sclerosis, due primarily to the actions of TGF and CTGF. Increased prostanoid synthesis, 
possibly modulated by TGF, may also have a role in this process. Therapeutic interventions, 
which target mesangial cell proliferation or matrix production, can therefore greatly 
ameliorate both acute and chronic forms of glomerular injury in those disorders in which 
glomerular cell proliferation is prominent. 
The relative inability of podocytes to replicate in response to injury may lead to their 
stretching along the GBM, expressing areas of denuded Glomerular basement membrane 
(GBM) that would attract and interact with parietal epithelial cells leading to the formation 
of capsular adhesions and subsequent segmental glomerulosclerosis. This may lead to the 
accumulation of amorphous material in the paraglomerular space and the subsequent 
disruption of glomerular-tubular junction resulting in atubular glomeruli.  
6.1 Extrinsic cells 
Neutrophils: Neutrophils are present in the early biopsies of patients with post-
streptococcal glomerulonephritis (GN), membranoproliferative GN, Henoch-Schönlein 
purpura (HSP), systemic lupus erythematosus (SLE), and some forms of rapidly progressive 
glomerulonephritis (RPGN) [Ishida-Okawara et al., 2004; Tipping & Holdsworth, 2003).  
Neutrophil localization in glomerular capillaries is dependent upon the generation of 
chemotactic factors within and around an inflammatory focus; the most prominent chemo-
attractants in glomerular disease are C5a (derived from activation of complement) and 
several chemokines, such as interleukin-8, which can be bound to endothelial cells via 
heparan sulfate proteoglycans (Segerer et al., 2000; De Vriese et al., 1999; Kitching et al., 
2002; Rops et al., 2004; Johnson et al., 2001; Segerer & Schlondorff, 2007). 
Once attracted, neutrophil localization involves the interaction between adhesion molecules 
expressed on glomerular endothelial cells, such as selectins, integrins (CD11/CD18), and Ig-
like molecules (ICAM-1), and their corresponding ligands on the neutrophil (Segerer et al., 
2000; De Vriese et al., 1999; Johnson et al., 2001; Ito et al., 2001).  
At the site of immune deposit formation, neutrophils phagocytose the immune complex 
aggregates, become activated and undergo a respiratory burst that generates reactive 
oxygen species (Johnson et al., 1987). Several studies have shown hydrogen peroxide to be 
the principal neutrophil-derived oxidant that mediates glomerular injury. Hydrogen 
peroxide is nephritogenic because of interactions with another neutrophil-derived cationic 
enzyme myeloperoxidase (MPO) (which also localizes in glomeruli because of charge) and a 
halide to form hypohalous acids, which halogenate the glomerular capillary wall (Johnson 
et al., 1987; Johnson et al., 2001). 
Neutrophils also store cationic serine proteases, such as elastase and cathepsin G, within 
azurophilic granules. The activation of neutrophils within glomeruli causes the extracellular 
release of these proteins, thereby resulting in the degradation of elements of the glomerular 
capillary wall. MPO and PR3, both cationic proteases localized in the primary granules of 
neutrophils, are also involved in the pathogenesis of ANCA-positive crescentic 
glomerulonephritis; they are localized in primary granules and displayed on the cell surface 
in response to certain cytokines. There they are accessible to ANCA antibody and become 
activated, resulting in capillary localization and release of oxidants and proteases (Xiao et 
al., 2005).  Evidence in animal models suggests that ANCA-neutrophil interaction also 
induces release of a complement-activating factor that contributes to the mediation of injury 
(Huugen et al., 2007; Jennete & Falk, 2008). 
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Macrophages: Macrophages are also prominent constituents of several glomerular lesions, 
particularly ones that exhibit crescent formation such as RPGN, SLE, and cryoglobulinemic 
nephropathy (Hooke et al., 1987; Rastaldi et al., 2000; Kurts et al., 2007). The importance of 
monocytes/macrophages in mediating glomerular injury is well-documented by studies, such 
as macrophage depletion and inhibition of macrophage inhibitory factor (MIF) (Kurts et al., 
2007). The protective effect of absent granulocyte macrophage colony stimulating factor is 
illustrated in GM-CSF -/- mice, which exhibited less infiltration of monocytes compared to 
wild type and were protected from crescentic glomerular injury (Timoshanko et al., 2005). 
Macrophages localize to glomeruli via interactions with both deposited immunoglobulins 
(through Fc receptors) and several chemokines, such as macrophage chemo-attractant 
protein-1 (MCP-1) and macrophage inflammatory protein-1-alpha (MIP-1alpha) and 
RANTES (Timoshanko et al., 2005; Shimizu et al., 2003). Unlike neutrophils, macrophages 
are also readily recruited by lymphocyte-derived molecules, such as MIF, that result from 
the interaction between specifically sensitized T-cells and intraglomerular antigens (Chitalia 
et al., 2001). In addition, monocytes also localize through interaction with leukocyte 
adhesion molecules, such as ICAM-1 and VCAM-1, as well as osteopontin (Kurts et al., 2007; 
Okada et al., 2000). 
Thus, macrophages may serve as effector cells in both humoral and cell-mediated forms of 
immune injury and are presumed to be the principal effector cells in inflammatory 
glomerular lesions induced by sensitized T-cells in the absence of antibody (Kurts et al., 
2007). As with neutrophils, macrophages may generate oxidants and proteases. However, 
unlike neutrophils, they release tissue factor (which initiates fibrin deposition and crescent 
formation) and TGF beta (which contributes to the synthesis of extracellular matrix and 
eventual development of sclerosis). 
T cells:  T cells are rarely conspicuous in glomerular lesions, but can be detected, particularly 
in diseases primarily mediated by macrophages such as crescentic GN (Tipping & 
Holdsworth, 2003; Hooke et al., 1987; Kurts et al., 2007). Although there is experimental 
evidence that glomerular injury can be induced by systemic T-cells in the absence of antibody 
deposition, little evidence exists that glomerular T-cells alone are nephritogenic, with the 
exception of permeability factors (Renneke et al., 1994). Instead, T-cell mediated injury occurs 
primarily via the release of chemokines and recruitment of macrophages, which subsequently 
function as effector cells. In addition, T cells may be the source of permeability factors that 
contribute to non-inflammatory glomerular injury (Kurts et al., 2007). 
Platelets:  Platelets are prominent in several glomerular lesions, usually ones that involve 
intraglomerular thrombosis such as SLE, anti-phospholipid antibody syndromes, and 
thrombotic microangiopathies. In addition to their role in thrombotic processes involving 
endothelial cell injury, platelets also release a number of products that participate in and 
augment glomerular injury, more broadly including vasoactive, mitogenic, and chemotactic 
substances (Barnes, 2001). For example, platelet-derived factors such as PAF and platelet 
factor 4 enhance glomerular permeability to proteins and immune complex deposition, and 
PDGF and TGF contribute to mesangial cell proliferation and sclerosis, respectively. 
Platelets have also been shown to contribute to neutrophil-mediated glomerular injury 
through non-chemotactic mechanisms. 
6.2 Tubulo-interstitial disease (fibrosis)   
All forms of CKD are associated with marked tubulointerstitial injury (tubular dilatation, 
interstitial fibrosis), even if the primary process is a glomerulopathy (Ong & Fine, 1994; 
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Nath, 1982). Furthermore, the degree of tubulo-interstitial disease is a better predictor of the 
GFR and long-term prognosis than is the severity of glomerular damage in almost all 
chronic progressive glomerular diseases, including IgA nephropathy, membranous 
nephropathy, membranoproliferative glomerulonephritis, and lupus nephritis (Nath, 1982; 
D’Amico, 1992; Alexopoulos et al., 1990; Bajema et al., 1999; Bazzi et al., 2002; Meyer, 2003). 
It is possible in these settings that tubulointerstitial disease causes tubular atrophy and/or 
obstruction, eventually leading to nephron loss. 
The mechanism by which tubulointerstitial fibrosis develops is incompletely understood 
[Alexopoulos et al., 1990; Lan et al., 1991; Eddy, 1994; Nath, 1998). Infiltration of the 
kidney by macrophage and T lymphocytes (and perhaps bone marrow derived fibroblast-
like cells), resulting in the subsequent production of transforming growth factor beta 
(TGF-beta) and other profibrotic factors, may be central to the development of this process 
(Lan et al., 1991). 
Other possible contributors include calcium phosphate deposition, and metabolic acidosis 
with secondary interstitial ammonia accumulation. 
6.3 Angiotensin II   
Non-hemodynamic effects of angiotensin II also appear to contribute to the development of 
tubulointerstitial fibrosis, mediated via one of the angiotensin II type 1 receptors that are 
present in the glomerulus (Ruiz-Ortega et al., 2006). Animal studies have suggested that 
activation of angiotensin II receptor type 1B, which is largely limited to the glomerulus, but 
not type 1A, may accelerate renal injury (Crowly et al., 2009). This effect is likely due to the 
generation of profibrotic factors such as TGF-beta, connective tissue growth factor, 
epidermal growth factor, and other chemokines (Aros & Remuzzi, 2002). Further support 
for this role is provided by the finding that the expression of angiotensin II type 1 receptors 
in podocytes is associated with focal segmental glomerulosclerosis (Hoffmann et al., 2004). It 
also appears that renin may lead to a receptor-mediated increase in TGF-beta that is 
independent of angiotensin II (Huang et al., 2006). 
Actions of angiotensin II may also be mediated via epidermal growth factor (EGF) receptors, 
which are present throughout the nephron, and when stimulated, promote cell proliferation 
and collagen production via transforming growth factor-alpha (TGF-alpha), EGF, and other 
growth factors (Lautrette et al., 2005; Chen et al., 2006). In experimental models, infusion of 
angiotensin II induces glomerulosclerosis and tubular atrophy. This effect is not seen in 
mice lacking EGF receptors or TGF-alpha, and pharmacologic inhibition of angiotensin II 
prevented these renal lesions. Angiotensin II also participates in cytokine- and chemokine- 
mediated recruitment of inflammatory cells into the kidney. 
6.4 Vascular sclerosis 
Vascular sclerosis is an integral feature of the renal scarring process. Renal arteriolar 
hyalinosis is present in CKD at an early stage, even in the absence of severe hypertension. 
Vascular sclerosis is associated with progressive renal failure in glomerulonephritis. 
Hyalinosis of afferent arterioles has been implicated in the pathogenesis of diabetic 
glomerulosclerosis. Changes in postglomerular arterioles and damage to peritubular 
capillaries may further exacerbrate interstitial ischemia and fibrosis. Ischemia and the 
ensuing hypoxia are fibrogenic influences that stimulate tubular cells and renal fibroblast to 
produce ECM components and reduce their collagenolytic activity.  
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7. Factors affecting progression of chronic kidney disease 
A variety of chronic kidney diseases progress to ESRD, including chronic glomerulonephritis, 
diabetic nephropathy, and polycystic kidney disease. Although the underlying problem often 
cannot be treated, extensive studies in experimental animals and humans suggest that 
progression in CKD may be largely due to secondary factors that are sometimes unrelated to 
the activity of the initial disease. These include systemic and intraglomerular hypertension, 
glomerular hypertrophy, the intrarenal precipitation of calcium phosphate, hyperlipidemia, 
and altered prostanoid metabolism (tables 2, 3). (Jacobson, 1991; Renneke et al., 1989; 
Loghman-Adham, 1993; Nagata & Kriz, 1942; Yu, 2003). 
7.1 Genetic factors  
A number of genetic factors (eg, single nucleotide polymorphisms and modifier genes) 
may influence the immune response, inflammation, fibrosis, and atherosclerosis, possibly 
contributing to accelerated progression of CKD (Nordfors et al., 2005; Hsu et al., 2006). 
Indirect evidence in support of such factors can be found in familial clustering of all-cause 
ESRD, with approximately one-quarter of dialysis patients having relatives with ESRD 
(Freedman et al., 2005). This is consistent with the hypothesis that common kidney 
diseases and progression to ESRD are influenced by the inheritance of specific genes. 
Genetic studies have suggested possible links between CKD and a variety of alterations or 
polymorphisms of genes coding for putative mediators including the renin angiotensin 
system, nitric oxide synthase, kallikrein, growth factors including platelet-derived growth 
factors and cytokines. 
With respect to specific genes, apolipoprotein E (ApoE) polymorphisms may alter the risk of 
atherosclerotic disease, and, therefore, progression of CKD. The ApoE epsilon-2 allele is 
associated with elevated lipoprotein and triglyceride levels, whereas the ApoE epsilon-4 allele 
is associated with elevated levels of high density lipoprotein and lower triglycerides. In a 
secondary analysis of the Atherosclerosis Risk in Communities Study of 14, 520 patients with a 
median follow-up of 14 years, individuals with an ApoE epsilon-4 allele (present in 30 percent) 
had a 15 percent reduction in risk of progression of CKD compared to individuals with ApoE 
epsilon-3 allele (present in 90 percent) (Hsu et al., 2005). The risk with the ApoE epsilon-2 allele 
was not significantly different compared with ApoE epsilon-3. 
 
Risk  factors Definition 
Susceptibility factors 
Factors predisposing to CKD include genetic and familial 
predisposition, race, maternal-fetal factors (low birth weight, 
malnutrition in utero), age (elderly), gender (male) 
Initiation factors 
Factors directly trigger kidney damage include diabetes, 
hypertension, cardiovascular disease, dyslipidemia, obesity, 
hyperuricemia and nephrotoxin exposure 
Progression factors 
Factors associated with worsening of already established kidney 
damage include poor glycemia control, poor blood pressure 
control, cardiovascular disease, proteinuria, alcohol 
consumption, nephrotoxin exposure, and acute kidney injury 
Table 2. Types of risk factors for chronic kidney disease and its outcomes. 
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Intraglomerular hypertension and hypertrophy  
Phosphate retention, with interstitial CaPO4 deposition  
Increased prostaglandin synthesis  
Hyperlipidemia, especially in the nephrotic syndrome  
Metabolic acidosis 
Obesity 
Smoking 
Type of underlying kidney disease 
Proteinuria  
Tubulointerstitial disease  
Retained "uremic" toxins  
Filtered iron in nephrotic syndrome  
Table 3. Secondary factors and progression of CKD. 
7.2 Hypertension 
Systemic hypertension is both a cause and consequence of CKD. The incidence of 
hypertension increases as CKD advances. The prevalence of hypertension requiring 
treatment in patients with stage 4 CKD is greater than 80%. There is strong evidence that 
high blood pressure is a risk factor for the progression of CKD in humans.  It is believed that 
the transmission of systemic hypersion into the glomerular capillary beds and the resulting 
glomerular hypertension contribute to the initiation of glomerulosclerosis and, there is clear 
evidence that strict control of the blood pressure is beneficial in slowing the rate of 
progression of CKD. 
7.3 Proteinuria 
Proteinuria alone may contribute to disease progression (Burton & Harris, 1996; Eddy et al., 
1991; Benigini et al., 2004; Hirschberg & Wang, 2005). Proposed mechanisms include 
mesangial toxicity, tubular overload and hyperplasia, toxicity from specific filtered 
compounds such as transferrin/iron and albumin-bound fatty acids, and induction of 
proinflammatory molecules such as MCP-1 and inflammatory cytokines (Wang et al., 1997). 
It is possible, for example, that a marked increase in protein filtration and subsequent 
proximal reabsorption leads to tubular cell injury and the release of lysozymes into the 
interstitium. To the degree that proteinuria alone might be important, reversing 
intraglomerular hypertension with protein restriction or antihypertensive therapy may be 
beneficial both by diminishing hemodynamic injury to the glomeruli and by reducing 
protein filtration (which is in part dependent upon the intraglomerular pressure), thereby 
lowering proteinuria. 
7.4 Hyperlipidemia 
Hyperlipidemia is common in patients with CKD, particularly those with the nephrotic 
syndrome. In addition to accelerating the development of systemic atherosclerosis, 
experimental studies suggest that high lipid levels also may promote progression of the 
renal disease (Keane, 1994; Grone & Grone, 2008). The major experimental evidence in 
support of this hypothesis are the observations in experimental animals that cholesterol 
loading enhances glomerular injury and that reducing lipid levels with a drug such as 
lovastatin slows the rate of progressive injury (Keane, 1994; Diamond & Karnovsky, 1987; 
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Rubin et al., 1994; Michel et al., 1997). Furthermore, the beneficial effect of lipid lowering 
may be additive to that of lowering the blood pressure in at least some models of CKD 
(Rubin et al., 1994). 
The factors responsible for the lipid effects are incompletely understood. In different animal 
models, a high cholesterol intake may be deleterious in association with a rise in 
intraglomerular pressure (Diamond & Karnovsky, 1987), while lipid-lowering agents may 
be beneficial without affecting glomerular hemodynamics. These disparate observations 
suggest that mechanisms other than intraglomerular pressure alone may play a contributory 
role. It has been shown experimentally, for example, that hyperlipidemia activates the 
mesangial cells (which have LDL receptors), leading to stimulation of mesangial cell 
proliferation and to increased production of macrophage chemotactic factors, fibronectin (a 
component of the extracellular matrix), type IV collagen, plasminogen activator-1 and 
reactive oxygen species. 
Each of these changes could contribute to glomerular injury. In addition, statins may act 
independent of plasma lipid levels by directly inhibiting mesangial cell proliferation and 
production of monocyte chemo-attractants. 
The applicability of these findings to human disease is uncertain. There are numerous 
secondary analyses of data from lipid trials suggesting that high lipid levels are associated 
with a faster rate of progression, and that statins slow the rate of progression of kidney failure. 
7.5 Hyperuricemia 
Hyperuricemia can develop in patients with CKD due to decreased urinary excretion. It has 
been proposed that hyperuricemia may contribute to progression, in part by decreasing renal 
perfusion via stimulation of afferent arteriolar vascular smooth muscle cell proliferation (Ohno 
et al., 2001; Iseki et al., 2004; Sanchez-Lozada et al., 2005; Schwarz et al., 2006). 
Combined data from two community-based cohorts comprising 13,388 individuals were 
examined for an association between baseline uric acid and the development of CKD during 
9 years of follow-up. Baseline uric acid was associated with increased risk for CKD with 
odds ratios of 1.07 (95% CI 1.01 to 1.14) and 1.11 (95% CI 1.02 to 1.21) per 1 mg/dl increase 
in uric acid, in both GFR and serum creatinine based models. 
In a Japanese study, hyperuricemic patients with IgA nephropathy had a worse prognosis 
than those with normal uric acid level, and a serum uric acid greater than 6mg/dl was an 
independent predictor of ESRD in women. 
7.6 Phosphate retention  
A tendency to phosphate retention is an early problem in kidney disease, beginning as soon 
as the GFR starts to fall. In addition to promoting bone disease, the excess phosphate also 
may contribute to progression of CKD. Higher serum phosphorus concentrations have been 
associated with a greater risk of progression. In an observational study of 985 patients 
followed for a median of two years, the adjusted hazard ratio for doubling of the serum 
creatinine was 1.3 for every 1.0 mg/dl [0.33 mmol/l] increase in serum phosphorus 
(Schwarz et al., 2006). 
A similar relationship was noted for the calcium-phosphorus product. 
A potential causative mechanism could be calcium phosphate precipitation in the renal 
interstitium (Gimenez et al., 1987), which might initiate an inflammatory reaction, resulting 
in interstitial fibrosis and tubular atrophy. 
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These observations do not prove a cause-and-effect relationship and there are no data 
addressing the possible role of improved calcium and phosphorus control in slowing the 
progression of CKD. However, there are other compelling reasons for optimizing 
phosphorus control in patients with CKD.  
7.7 Type of underlying kidney disease 
The type of kidney disease appears to be a risk factor. Glomerulonephritis, diabetic and 
hypertensive nephropathies, and polycystic kidney disease tend to progress faster than 
tubulointerstitial disease. 
7.8 Metabolic acidosis and increased ammonium production 
As the number of functioning nephrons declines, each remaining nephron excretes more 
acid (primarily as ammonium). The local accumulation of ammonia can directly activate 
complement, leading to secondary tubulointerstitial damage (at least in experimental 
animals) (Nath et al., 1985). On the other hand, buffering the acid with alkali therapy 
prevents the increase in ammonium production and minimizes the renal injury. Although 
the renal protective effect of alkali therapy is unproven in humans, there are other reasons 
(prevention of osteopenia and muscle wasting) why correction of the acidemia might be 
desirable.  
7.9 Smoking 
Cigarette smoking increases systemic blood pressure and affects renal hemodynamics. In 
diabetic and non-diabetic patients, smoking is associated with a faster rate of decline of 
CKD. In one study of men with CKD, smoking increased the risk for ESRD threefold in 
patients treated with ACE inhibitors; with the odds ratio increasing to 10 in those taking 
other antihypertensive agents. 
8. Clinical manifestations of chronic kidney disease 
A wide range of disorders may develop as a consequence of the loss of renal function. In the 
early phase, stage 1 and 2, the patient is asymptomatic, blood urea nitrogen (BUN) and 
serum creatinine (SCr) are normal or near-normal, and acid base, fluid, and electrolyte 
balances are maintained through an adaptive increase of function in the remaining 
nephrons. A reduction of GFR to 30 to 59 ml/min/1.73 m2 define stage 3, moderate 
impairment of GFR. The patient usually has no symptoms, although SCr and BUN  are 
increased, and serum levels of hormones such as erythropoietin, calcitriol, and parathyroid 
hormones (PTH) are usually abnormal. Stage 4, severe impairment of GFR, involves a 
further loss of kidney function. Finding, if present, are mild; patients may have anemia, 
acidosis, hypocalcemia, hyperphosphatemia and hyperkalemia. The final stage of kidney 
disease, stage 5 is defined by a GFR of less than 15ml/min/1.73 m2, is usually characterized 
by worsening of all the aforementioned findings, and symptoms including fatigue, 
dysgeusia, anorexia, nausea, and pruritis may develop. 
8.1 Hypertension 
Hypertension is present in approximately 80 to 85 percent of patients with CKD [MMWR, 
2007]. The prevalence of hypertension increases linearly as the GFR falls and, as in patients 
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without renal disease, is increased in patients with higher body weight and in blacks. Data 
from the Modification of Diet in Renal Disease Study, for example, showed that the 
prevalence of hypertension rose progressively from 65 to 95 percent as the GFR fell from 85 
to 15 ml/min per 1.73 m2 (Buckalew et al., 1996). 
One or more of the following factors may contribute in the individual patient: 
• Sodium retention is generally of primary importance, even though the degree of 
extracellular volume expansion may be insufficient to induce edema. 
• Increased activity of the renin-angiotensin system (probably due to regional ischemia 
induced by scarring) is often responsible for at least part of the hypertension that 
persists after the restoration of normovolemia. 
• Enhanced activity of the sympathetic nervous system has been demonstrated in 
patients with CKD. The afferent signal may arise in part within the failing kidneys, 
since it is not seen in patients who have undergone bilateral nephrectomy (Ligtenberg 
et al., 1999; Neumann et al., 2004). 
Secondary hyperparathyroidism raises the intracellular calcium concentration, which can 
lead to vasoconstriction and hypertension (Raine et al., 1993). Lowering parathyroid 
hormone secretion by the chronic administration of an active vitamin D analog can reduce 
both intracellular calcium and the systemic blood pressure. 
• Hypertension may occur or be exacerbated in patients with advanced CKD treated with 
erythropoietin; this effect is in part related to the degree of elevation in the hematocrit. 
• Impaired nitric oxide synthesis and endothelium-mediated vasodilatation has been 
demonstrated in patients with uremia (Passauer et al., 2005; Passauer et al., 2005). 
Although the mechanisms are unclear, potential explanations include reduced nitric 
oxide availability due to a state of increased oxidative stress, or cofactor deficiency-
induced uncoupling of nitric oxide synthase. 
In addition to these factors that can raise the mean arterial pressure, two other factors may 
be important: 
• Patients with end-stage renal disease are more likely to have an increase in pulse 
pressure and isolated systolic hypertension (London et al., 1992). Why this occurs is 
incompletely understood but increased aortic stiffness appears to play an important 
role. 
• Patients with CKD may not demonstrate the normal nocturnal decline in blood 
pressure (called "nondippers"), a possible risk factor for hypertensive complications. 
The optimal blood pressure in hypertensive patients with CKD is uncertain. The rate of loss 
of GFR appears to be more rapid when the mean arterial pressure remains at or above 100 
mmHg (which reflects a diastolic pressure of 80 to 85 mmHg in the absence of systolic 
hypertension). To slow progression of CKD, the optimal blood pressure depends in part on 
the degree of proteinuria.  
We recommend a blood pressure goal of less than 130/80 mmHg, which is consistent with 
JNC 7 and the K/DOQI Clinical Practice Guidelines on hypertension and antihypertensive 
agents in CKD. However, evidence from the Modification of Diet in Renal Disease study, the 
AASK trial, and a meta-analysis from the ACE inhibition and Progressive Renal Disease 
(AIPRD) study group suggest that an even lower systolic pressure may be more effective in 
slowing progressive renal disease in patients with a spot urine total protein-to-creatinine 
ratio =1000 mg/g (which represents protein excretion of greater than 1000 mg/day). 
Caution is advised about lowering the systolic blood pressure below 110 mmHg. 
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The desired degree of blood pressure control typically requires combination therapy in 
patients with CKD. The regimen should include an ACE inhibitor or angiotensin II receptor 
blocker, which are the preferred drugs to prevent progressive proteinuric CKD, and a 
diuretic for fluid control  
A loop diuretic is recommended for the treatment of hypertension and edema in patients 
with CKD. The thiazide diuretics in conventional dosage become less effective as 
monotherapy when the GFR falls below 20 ml/min. They do, however, produce an additive 
effect when administered with a loop diuretic for refractory edema. 
Calcium channel blockers are also effective in the hypertension of CKD. These agents are 
relatively unique in that they seem to be more effective in patients who are volume 
expanded. 
8.2 Volume overload 
Sodium and intravascular volume balance are usually maintained via homeostatic 
mechanisms until the GFR falls below 10 to 15 ml/min. However, the patient with mild to 
moderate CKD, despite being in relative volume balance, is less able to respond to rapid 
infusions of sodium and is therefore prone to fluid overload. As kidney function declines, 
most patients develop sodium retention and extracellular volume expansion. They may 
complain of ankle swelling or shortness of breath as a result of pulmonary edema.  
Patients with CKD and volume overload generally respond to the combination of dietary 
sodium restriction and diuretic therapy, usually with a loop diuretic given daily. 
8.3 Anemia 
Anemia has been defined by the World Health Organization (WHO) as a hemoglobin (Hgb) 
concentration below 13.0 g/dl for adult males and post-menopausal women, and a Hgb below 
12.0 g/dl for pre-menopausal women . Based upon these criteria, nearly 90 percent of patients 
with a GFR less than 25 to 30 ml/min have anemia, many with Hgb levels below 10 g/dl. 
Anemia is an almost universal complication of CKD. It contributes considerably to reduced 
quality of life of patients with CKD and has been increasingly recognized as an adverse risk 
factor. Renal anemia is typically an isolated normochromic, normocytic anemia with no 
leukopenia or thrombocytopenia.    
It is principally due to reduced renal erythropoietin production and, to a lesser degree, to 
shortened red cell survival and decreased responsiveness to the hormone. 
Anemia can develop well before the onset of uremic symptoms due to ESRD and is a 
common feature in many patients with CKD who do not require dialysis, with decreasing 
hemoglobin levels as GFRs decline below 60 ml/min per 1.73 m2. As an example, based 
upon over 15,000 participants in the NHANES survey, the prevalence of anemia (Hbg <12 
g/dL in men and <11 g/dL in women) increased from one percent at an estimated GFR of 
60 ml/min per 1.73 m2 to 9 percent at an estimated GFR of 30 ml/min per 1.73 m2 and to 33 
to 67 percent at an estimated GFR of 15 ml/min per 1.73 m2. Kazmi et al. (2001) in a study on 
anemia in pre-dialysis patients have demonstrated that even among CKD patients in the 
serum creatinine <2mg/dl category, 24% of the patients had hemoglobin levels <11g/dl 
(Figure 1). Anemia has also been implicated as a contributing factor in many of the 
symptoms associated with reduced kidney function. These include fatigue, depression, 
reduced exercise tolerance, dyspnea, and cardiovascular consequences, such as left 
ventricular hypertrophy (LVH) and left ventricular systolic dysfunction. It is also associated 
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with an increased risk of morbidity and mortality principally due to cardiac disease and 
stroke, and with an increased risk of hospitalization, hospital length of stay, and mortality in 
patients with predialysis CKD. 
 
 
Fig. 1. Prevalence of anemia in patients with different stages of CKD (Kazmi et al.,  
Am J Kidney Dis, 2001). 
8.4 Hyperkalemia 
The ability to maintain potassium excretion at near normal levels is generally maintained in 
patients with renal disease as long as both aldosterone secretion and distal flow are 
maintained (Gonik et al., 1971; Hsu & Chertow, 2002). Thus, hyperkalemia generally 
develops in the patient who is oliguric, or who has an additional problem such as a high 
potassium diet, increased tissue breakdown, or hypoaldosteronism (due in some cases to the 
administration of an ACE inhibitor or ARB) (Gennari & Segal, 1995). Impaired cell uptake of 
potassium also may contribute to the development of hyperkalemia in advanced CKD. 
Unlike patients with acute kidney failure, those with CKD may tolerate high plasma 
potassium concentrations without electrocardiographic changes or arrhythmias.  
Hyperkalemia due to ACE inhibitor or ARB therapy is most likely to occur in patients in 
whom the serum potassium concentration is elevated or in the high normal range prior to 
therapy. In this setting, institution of a low-potassium diet or concurrent use of a loop 
diuretic (to increase urinary potassium losses) often ameliorates the degree of hyperkalemia. 
In selected patients, low dose Kayexalate (5 grams with each meal) can be used to lower the 
serum potassium concentration without the side effects associated with larger doses. In 
addition to treating hyperkalemia, there are several measures that can help prevent 
hyperkalemia in patients with CKD. These include ingestion of a low potassium diet (eg, 
less than 40 to 70 meq/day [1500 to 2700 mg/day]) and avoiding, if possible, the use of 
drugs that raise the serum potassium concentration such as nonsteroidal antiinflammatory 
drugs (Allon, 1995). Nonselective beta-blockers make the postprandial rise in the serum 
potassium concentration but do not produce persistent hyperkalemia.   
Spontaneous hypokalemia is uncommon in CKD, but it can be seen in salt wasting 
nephropathy, Fanconi’s syndrome, hereditary or acquired tubulointerstitial disease, and 
renal tubular acidosis .in patients with CKD, hypokalemia is usually caused by low dietary 
potassium intake combined with high doses of diuretics or by gastrointestinal loss.  
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8.5 Metabolic acidosis 
There is an increasing tendency to retain hydrogen ions among patients with CKD. (Uribarri 
et al., 1995; Warnock, 1988; Widmer et al., 1979). This can lead to a progressive metabolic 
acidosis with the serum bicarbonate concentration tending to stabilize between 12 and 20 
meq/l, and rarely falling below 10 meq/l (Warnock, 1988; Walia et al., 1986). 
Previously, exogenous alkali was not usually given to treat the generally mild metabolic 
acidosis (arterial pH generally above 7.25) in asymptomatic adults with CKD. This was 
primarily due to concerns related to the exacerbation of volume expansion and 
hypertension. However, these concerns appear to be overstated. The treatment of acidosis is 
desirable to prevent osteopenia and muscle catabolism. In fact, bone buffering of some of 
the excess hydrogen ions is associated with the release of calcium and phosphate from bone, 
which can worsen the bone disease. Uremic acidosis can increase skeletal muscle 
breakdown and diminish albumin synthesis, leading to loss of lean body mass and muscle 
weakness. The administration of bicarbonate increases serum albumin and the lean body 
mass (de Brito-Ashurst et al., 2009). 
It is now recommended to start alkali therapy to maintain the serum bicarbonate concentration 
above 23 meq /l (de Brito-Ashurst et al., 2009). If alkali is given, sodium bicarbonate (in a daily 
dose of 0.5 to 1 meq/kg per day) is the agent of choice. Sodium citrate (citrate is rapidly 
metabolized to bicarbonate) may be used in patients who are unable to tolerate sodium 
bicarbonate, since it does not produce the bloating associated with bicarbonate therapy. 
Sodium citrate should be avoided in the rare patient who may be taking aluminum-containing 
antacids since it markedly enhances intestinal aluminum absorption. 
An alternative method to correct the metabolic acidosis in patients on maintenance dialysis 
is to increase the bicarbonate concentration in the dialysate. Levels as high as 42 meq/l may 
be required with hemodialysis to prevent predialysis acidosis. This regimen is generally 
well tolerated and does not induce significant postdialysis alkalosis.  
8.6 Renal osteodystrophy 
Four main types of renal bone disease can be seen in patients with CKD. These are osteitis 
fibrosa cystica, adynamic bone disease, osteomalacia, and mixed renal osteodystrophy, with 
the last disorder being a mixture of the first three. The prevalence of the different types of 
bone disease has changed over the last several decades. At present, the most common 
disorder is adynamic bone disease, with osteitis fibrosa, osteomalacia, and mixed disease 
less frequently observed. 
A tendency toward phosphate retention begins early in renal disease, due to the reduction 
in the filtered phosphate load. Although this problem is initially mild with 
hyperphosphatemia being a relatively late event, phosphate retention is intimately related to 
the common development of secondary hyperparathyroidism that play an important role in 
the pathogenesis of bone disease and in other uremic complications. 
Dietary phosphate restriction may limit the development of secondary hyperparathyroidism 
in patients with CKD. An intake of about 800 mg/day may be desirable and is recommended 
by the K/DOQI guidelines in patients with elevated phosphate and/or PTH levels.  
Once the GFR falls below 25 to 30 ml/min, the addition of oral phosphate binders are usually 
required to prevent hyperphosphatemia (Abboud & Henrich, 2010; Sarnak et al., 2005). The 
K/DOQI guidelines recommend that serum phosphorus levels should be between 2.7 and 4.6 
mg/dl (0.87 and 1.49 mmol/l) among patients with stage 3 and 4 CKD, and between 3.5 and 
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5.5 mg/dl (1.13 and 1.78 mmol/l) among those with ESRD (or stage 5 disease) (Sarnak et al., 
2005). Patients are also prescribed biologically active vitamin D e.g calcitriol or vitamin D 
prohormones that are converted to active dihydroxylated compounds in the liver.  
8.7 Malnutrition 
Malnutrition is common in patients with advanced chronic renal disease because of a lower 
food intake (principally due to anorexia), decreased intestinal absorption and digestion, and 
metabolic acidosis (Kopple et al., 2000; Garg et al., 2001; Bammens et al., 2003). Among 
participants =60 years of age in the United States NHANES III, a GFR <30 ml/min was 
independently associated with malnutrition (odds ratio of 3.6) (Garg et al., 2001). 
It is, therefore, desirable to monitor the nutritional status of patients with CKD. Biochemical 
indicators include a fall in serum albumin, transferrin, and cholesterol. Weight should be 
carefully monitored in patients who progress to CKD stages 4 to 5 ,these should be 
measured approximately every one to three months for those with estimated GFRs <20 
ml/min, and more frequently if necessary for those with GFRs =15 ml/min.  
8.8 The uremic syndrome 
The uremic syndrome can be defined as deterioration of multiple biochemical and 
physiological function in parallel with progressive renal failure, thereby resulting in 
complex but variable symtomatology. A myriad of uremic retention solutes accumulates in 
the uremic patients with ESRD which are directly or indirectly attributable to deficient renal 
clearance that impair cell regulatory mechanisms involving the cardiovascular, 
gastrointestinal, hematopoietic, immune, nervous and endocrine systems. 
These retained solutes are called uremic toxins when they contribute to the uremic syndrome. 
The uremic syndrome is characterized not only by solute accumulation but also by hormonal 
alterations such as decreased production of erythropoietin and calcitriol, decreased clearance 
of insulin, end-organ resistance to insulin and PTH. The signs and symptoms vary from one 
patient to another, depending partly on the rate and severity of the loss of kidney function.  
Uremic toxins can be subdivided into three major groups based upon their chemical and 
physical characteristics: 
• Small, water-soluble, non-protein-bound compounds, such as urea 
• Small, lipid-soluble and/or protein-bound compounds, such as the phenols 
• Larger so-called middle-molecules, such as beta2-microglobulin 
8.9 Dyslipidemia 
Abnormal lipid metabolism is common in patients with renal disease. Patients with CKD stage 
3 develop a disturbance of lipoprotein metabolism characterized by accumulation of partially 
metabolized very-low-density lipoprotein particle and a disturbance in the maturation of high-
density-lipoprotein .The primary finding in CKD is hypertriglyceridemia with the total 
cholesterol concentration usually being normal (perhaps due in part to malnutrition in some 
patients). Patients with CKD should be assessed for dyslipidemia, including a total cholesterol, 
LDL, HDL, and triglycerides.  
Among patients with CKD, the degree of hypertriglyceridemia that occurs may not be 
sufficient to significantly increase coronary risk, but other changes have been found that might 
contribute to the accelerated atherosclerosis commonly seen in ESRD. First, dietary 
modification may be helpful for the hypertriglyceridemia. Drug therapy in patients without 
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renal failure may be beneficial in selected patients with isolated marked hypertriglyceridemia 
(serum triglycerides =500 mg/dl [=5.65 mmol/l]) who have proven coronary disease, a strong 
family history of Coronary heart disease (CHD), or multiple coexisting cardiac risk factors. 
Whether this approach is beneficial in patients with renal failure is not known, but it should be 
considered. Fibrate dose should be reduced in any patient with CKD stage 3 to 4, and these 
agents are best avoided in those with stage 5 disease.  
In the patient with hypercholesterolemia, a statin can effectively and safely lower the 
plasma cholesterol concentration to or near acceptable levels, although low starting doses 
are recommended because of drug accumulation. The goal LDL-cholesterol is similar to that 
in patients with CHD, which has been less than 100 mg/dl (2.6 mmol/l).  
Limited data suggest that lipid lowering may have an additional benefit in patients with 
CKD, which is slowing the rate of progression of the underlying renal disease. 
8.10 Sexual dysfunction in females 
Disturbances in menstruation, fertility, and sexual dysfunction are commonly encountered 
in women with CKD, usually leading to amenorrhea by the time the patient reaches ESRD. 
The menstrual cycle typically remains irregular with scanty flow after the initiation of 
maintenance dialysis, although normal menses are restored in some women (Holley et al., 
1997; Peng et al., 2005). In others, menorrhagia develops, sometimes leading to significant 
blood loss and increased transfusion requirements. 
The major menstrual cycle abnormality in uremic women is anovulation, resulting in 
infertility. Women receiving chronic dialysis also tend to experience decreased libido and 
reduced ability to reach orgasm (Hou, 1999; Finkelstein et al., 2007). 
Although rare, pregnancy can occur in women with advanced kidney failure, but fetal wastage 
is markedly increased (Hou, 1999). Some residual renal function is usually present in the 
infrequent pregnancy that can be carried to term. Although luteinizing hormone levels are 
high, there is absence of the preovulatory peak in LH and estradiol concentrations. The failure 
of LH to rise in part reflects a disturbance in the positive estradiol feedback pathway, since the 
administration of exogenous estrogen to mimic the preovulatory surge in estradiol fails to 
stimulate LH release. In contrast, feedback inhibition of gonadotropin release by low doses of 
estradiol remains intact. This can be illustrated by the ability of the antiestrogen clomiphene to 
enhance luteinizing hormone (LH) and follicle stimulating hormone (FSH) secretion. 
Women with CKD commonly have elevated circulating prolactin concentrations and 
galactorrhea due to increased secretion and decreased metabolic clearance. The 
hypersecretion of prolactin in this setting appears to be relatively autonomous, as it is 
resistant to maneuvers designed to stimulate or inhibit its release. Similar observations have 
been made in uremic males.  
The elevated prolactin levels may impair hypothalamic-pituitary function and contribute to 
sexual dysfunction and galactorrhea in these patients. Bromocriptine treatment corrects the 
hyperprolactinemia in these patients but does not restore normal menses, thereby 
suggesting that other mechanisms are involved. 
8.11 Sexual dysfunction in males 
Disturbances in sexual function are a common feature of chronic kidney disease (Palmer, 
2003; Holdsworth et al., 1978). Over 50 percent of uremic men complain of symptoms that 
include erectile dysfunction, decreased libido, and marked decline in the frequency of 
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intercourse (Diemont et al., 2000). Prolactin levels are elevated in CKD stage 5 and may 
contribute to gynecomastia and sexual dysfunction. Testosterone levels are often low-
normal, and gonadotropins may be raised, implying testicular failure. This is accompanied 
by poor spermatogenesis, leading to low sperm counts and reduced fertility.  These 
problems may improve, but rarely normalize with the institution of maintenance dialysis, 
commonly resulting in a decreased quality of life (Rosas et al., 2003). By comparison, a well-
functioning renal transplant is much more likely to restore sexual activity; however, some 
features of reproductive function may remain impaired, particularly reduced libido and 
erectile dysfunction. 
It is presumed that the uremic milieu plays an important role in the genesis of this problem. 
Other organic (and not necessarily uremic) factors that may contribute to erectile 
dysfunction include peripheral neuropathy, autonomic dysfunction, peripheral vascular 
disease, and pharmacologic therapy. 
8.12 Thyroid dysfunction 
The kidney normally plays an important role in the metabolism, degradation, and excretion of 
several thyroid hormones. It is not surprising, therefore, that impairment in kidney function 
leads to disturbed thyroid physiology. All levels of the hypothalamic-pituitary-thyroid axis 
may be involved, including alterations in hormone production, distribution, and excretion. 
As a result, abnormalities in thyroid function tests are frequently encountered in uremia. 
However, the overlap in symptomatology between the uremic syndrome and 
hypothyroidism requires a cautious interpretation of these tests. Nevertheless, it is 
ordinarily possible in the individual uremic patient to assess thyroid status accurately by 
physical diagnosis and thyroid function testing. 
Epidemiologic data suggests that predialysis patients with CKD have an increased risk of 
hypothyroidism (Lo et al., 2005; Chonchol et al., 2008). Many cases are subclinical. Free 
thyroxin [T4] and serum thyroid stimulating hormone [TSH] are usually normal but most 
patients with ESRD have decreased plasma levels of free triiodothyronine (T3), which reflect 
diminished conversion of T4 (thyroxine) to T3 in the periphery (Kaptein et al., 1988). This 
abnormality is not associated with increased conversion of T4 to the metabolically inactive 
reverse T3 (rT3), since plasma rT3 levels are typically normal. This finding differentiates the 
uremic patient from patients with chronic illness. In the latter setting, the conversion of T4 to 
T3 is similarly reduced, but the generation of rT3 from T4 is enhanced. 
8.13 Insulin metabolism 
Impaired tissue sensitivity to insulin occurs in almost all uremic subjects and is largely 
responsible for the abnormal glucose metabolism seen in this setting (Mak & DeFronzo, 1992). 
Both experimental and clinical studies suggest that hepatic glucose production and uptake 
are normal in uremia and that skeletal muscle is the primary site of insulin resistance 
(Androgue, 1992). How this occurs is not clear, but a post-receptor defect is of primary 
importance (Smith & DeFronzo, 1982). Furthermore, the abnormality appears to specifically 
involve glycogen synthesis, as the rate of glucose oxidation is relatively normal. It is of 
interest in this regard that other actions of insulin such as promoting potassium uptake by 
the cells, and inhibiting proteolysis are also maintained in renal failure. 
Accumulation of a uremic toxin or toxins and excess parathyroid hormone (PTH), resulting 
from abnormalities in phosphate and vitamin D metabolism are thought to be responsible 
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for the insulin resistance (McCaleb et al., 1985). As an example, the observation that tissue 
sensitivity to insulin can be substantially improved by dialysis is consistent with a role for 
uremic toxins. The expected response to impaired tissue sensitivity would be an 
augmentation in insulin secretion in an attempt to normalize glucose metabolism. In many 
cases, however, insulin secretion tends to be blunted; these patients tend to have the greatest 
impairment in glucose tolerance. 
One factor that can suppress insulin release in CKD is the associated metabolic acidosis. In 
addition, deficiency of calcitriol (1,25-dihydroxyvitamin D)  and excess PTH may interfere 
with the ability of the beta cells to augment insulin secretion in response to hyperglycemia 
or amino acids. A PTH-induced elevation in the intracellular calcium concentration may be 
responsible for the impairment in insulin release by decreasing both the cellular content of 
ATP and Na-K-ATPase pump activity in the pancreatic beta cells. 
There is little change in the metabolic clearance rate of insulin in renal disease until the GFR 
has fallen to less than 15 to 20 ml/min. At this point, there is a dramatic reduction in insulin 
clearance which is also mediated by a concomitant decline in hepatic insulin metabolism. 
The hepatic defect may be induced by a uremic toxin, since it is largely reversed with 
adequate dialysis. 
Insulin requirements show a biphasic course in diabetic patients with renal disease. It is not 
uncommon for glucose control to deteriorate as renal function deteriorates, as increasing 
insulin resistance can affect both insulin-dependent and non-insulin-dependent diabetics. 
Thus, insulin requirements may increase in the former, while the institution of insulin 
therapy may be necessary in the latter. 
In comparison, the marked fall in insulin clearance in advanced renal failure often leads to 
an improvement in glucose tolerance. This may allow a lower dose of insulin to be given or 
even the cessation of insulin therapy. Decreased caloric intake, due to uremia-induced 
anorexia, also may contribute to the decrease in insulin requirements. 
8.14 Hypoglycemia 
An unusual manifestation of disturbed glucose metabolism in CKD is the development of 
spontaneous hypoglycemia. This complication can be seen in both diabetic and nondiabetic 
subjects. As an example, in a retrospective analysis of 243,222 patients, the incidence of 
hypoglycemia was significantly higher among patients with CKD (defined as estimated GFR 
<60 ml/min per 1.73 m2) compared with patients without chronic kidney disease, both 
among those with diabetes (10.72 versus 5.33 per 100 patient-months, respectively) and 
without diabetes (3.46 versus 2.23 per 100 patient-months, respectively) (Moen et al., 2009). 
Multiple factors may play a contributory role. These include decreased caloric intake, 
reduced renal gluconeogenesis due to the reduction in functioning renal mass, impaired 
release of the counter-regulatory hormone epinephrine due to the autonomic neuropathy of 
renal failure, concurrent hepatic disease, and decreased metabolism of drugs that might 
promote a reduction in the plasma glucose concentration such as alcohol, propranolol and 
other nonselective -blockers, and disopyramide. 
8.15 Psychological manifestations 
Psychiatric illness is common among patients with chronic disorders, particularly in those 
with ESRD. In a review based upon United States Renal Disease Systems (USRDS) data 
(Kimmel et al., 1998) the psychological problems associated with CKD included affective 
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disorders, particularly depression, organic brain diseases eg, dementia and delirium drug-
related disorders (such as alcoholism), schizophrenia and other psychoses and personality 
disorders. 
These disorders account for a 1.5 to 3.0 times higher rate of hospitalization among dialysis 
patients compared to those with other chronic illnesses, thereby resulting in significant 
morbidity. In the previous study of approximately 175,000 dialysis patients, 9 percent were 
hospitalized with a mental disorder during a one-year period. A subsequent study from 
Japan reported a one-year 10.6 percent incidence of psychiatric disorders in dialysis patients 
(Fukunishi et al., 2002). Dementia, delirium, and major depression were the most common 
disorders in this four-year follow-up study. 
Patients maintained on hemodialysis are more likely to be hospitalized for a psychiatric 
disorder than are those treated with peritoneal dialysis. This difference may be due to 
patient selection for a particular dialysis modality or the increased incidence among 
hemodialysis patients of disruptive behaviors that may lead to hospitalization. Overall, the 
type of dialysis modality does not appear to have a significant impact upon symptoms 
related to depression, sexual function, and life satisfaction. 
8.16 Gastrointestinal manifestations 
Gastrointestinal complications are common in advanced CKD and in some cases may be the 
first or only complaint on presentation. Anorexia, nausea, vomiting, and uremic fetor are 
common manifestations of uremia. Vomiting may occur without nausea and is often 
prominent in the early morning. Stomatitis, gastritis and enteritis can develop with ESRD in 
patients not treated with dialysis or transplantation.  In one study of 60 patients with ESRD, 
panendoscopy revealed esophagitis, gastritis, and duodenitis in 13, 22, and 60 percent of 
patients, respectively, while biopsies showed histologic evidence of gastritis and duodenitis 
in 46 and 43 percent, respectively (Margolis et al., 1978). The incidence of gastritis appears to 
decline with increasing duration of dialysis. The pathogenesis of mucosal inflammation in 
these patients is unclear. 
In general, there is an increased risk of bleeding in hemodialysis patients because of uremia-
induced platelet dysfunction as well as the intermittent use of heparin with dialysis 
treatments. These systemic abnormalities may in part help explain the perceived higher 
incidence of upper gastrointestinal (UGI) bleeding in patients with ESRD. The causes of UGI 
bleeding among patients with ESRD may be somewhat different and a larger study found 
that angiodysplasia was a more frequent cause of upper GI bleeding in patients with renal 
failure compared to those without renal dysfunction. In this report, 727 patients with upper 
GI bleeding underwent diagnostic endoscopy. Among the 60 patients with CKD, the most 
common causes of bleeding were gastric ulcer (37 percent), duodenal ulcer (23 percent), and 
angiodysplasia (13 percent). Compared to patients without renal disease, angiodysplasia as 
a cause of UGI bleeding was significantly more common in those with renal failure (13 
versus 1.3 percent, P<0.01). 
Rarely, pancreatitis is a significant clinical problem  and additional reported risk factors in 
this patient population may include vascular disease, polycystic kidney disease, drug 
ingestion (possibly including valproic acid and iodixanol), and hyperparathyroidism. 
Lower gastrointestinal disorders of importance in CKD patients include uremic colitis 
(principally of historic interest), ischemic bowel disease, spontaneous colonic perforation, fecal 
impaction, diverticular disease, and angiodysplasia. A positive fecal occult blood test appears 
to be more informative as kidney function declines. One study of 531 patients with a positive 
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test, for example, found that clinical significant findings increased from 24 to 33 to 43 percent 
in patients with normal/stage 1 CKD, stage 2/3 CKD, and stage 4/5 CKD, respectively (Bini et 
al., 2006). Similar findings were observed with adenomas, carcinomas, and vascular ectasias. 
9. Prevention of progression of chronic kidney disease 
A kidney disease that progresses to ESRD usually does so by two mechanisms; those of 
primary kidney disease and those of natural progression. For most CKD patients, the first 
evidence of natural progression is proteinuria increasing from low to heavy levels. Only 
later does decreasing GFR appear. However, for certain diseases such as polycystic kidney 
disease, a decrease in GFR or the presence of hypertension may be the heralding features.  
9.1 Monitoring proteinuria 
Proteinuria magnitude generally is the strongest single predictor of GFR decline. Therapy-
induced proteinuria reduction slows GFR decline.The most detailed analysis of proteinuria 
and progression are from the Modification in Diet in Renal Disease and Ramipril Efficacy in 
nephropathy trials which show that for each 1.0gm reduction in proteinuria by 4 to 6 
months of the antiproteinuric intervention, GFR decline is slowed by about 1 to 2 
ml/min/yr. With regard to frequency of proteinuria testing, every 2 to 3 months for those 
with nephrotic range proteinuria and every 4 to 6 months for those with non-nephrotic 
proteinuria are usually sufficient to assess proteinuria trends. 
9.2 Monitoring GFR trends 
The GFR is equal to the sum of the filtration rates in all of the functioning nephrons; thus, 
estimation of the GFR gives an approximate measure of the number of functioning nephrons. 
A reduction in GFR implies either progression of the underlying disease or the development of 
a superimposed and often reversible problem, such as decreased renal perfusion due to 
volume depletion. An increase in GFR, on the other hand, is indicative of improvement in 
renal function, whereas a stable GFR in patients with renal disease implies stable disease. 
The most common methods utilized to estimate the GFR in adults are the serum creatinine 
concentration, the creatinine clearance, and estimation equations based upon the serum 
creatinine concentration: the Cockcroft-Gault equation and Modification of Diet in Renal 
Disease (MDRD) study equation.  
The K/DOQI working groups have published guidelines recommending that patients with 
CKD should be classified by disease stage, with each stage being defined in part by GFR 
estimation. In adults, the GFR should be estimated from the MDRD Study and Cockcroft-
Gault equations, which take into account the serum creatinine concentration and some or all 
of the following variables: age, gender, race, and body size. Since the MDRD Study equation 
was derived from patients (largely white) with nondiabetic renal disease (mean GFR of 40 
ml/min per 1.73 m2) in the United States, it can be reliably used in such patients with 
significant kidney disease. It also appears to be accurate in African-Americans and those 
with diabetic kidney disease.  
However, the estimation equations have not been validated, and may be less accurate, in 
some populations. These include individuals with high, normal, or near-normal renal 
function, children, certain ethnic groups, pregnant woman, and those with unusual muscle 
mass, body habitus, and weight (eg, morbid obesity or malnourished). Some therefore 
recommend measuring the creatinine clearance to estimate the GFR in these patients with 
stable renal function.  
www.intechopen.com
 
Chronic Kidney Disease Update 
 
223 
Serum creatinine and GFR estimation equations can only be used in patients with stable 
kidney function. With acute renal failure, for example, the GFR is initially markedly reduced 
but there has not yet been time for creatinine to accumulate and for the SCr to reflect the 
degree of renal dysfunction. 
What is important to know in the patient with kidney disease is whether the GFR (and 
therefore disease severity) is changing or is stable. This can usually be determined by 
monitoring changes in the serum creatinine or the estimated GFR in patients with a 
relatively constant body mass and diet. 
9.3 Angiotensin-converting enzyme inhibitors 
The degree of proteinuria in glomerular disease tends to vary directly with the 
intraglomerular pressure. It was, therefore, proposed that a treatment-induced reduction in 
protein excretion (in the absence of a large fall in GFR) reflected a desirable decline in 
intraglomerular pressure, and would result in improved renal outcomes. Although both 
angiogenesis-converting enzyme [ACE] inhibitors and angiotensin receptor blockers [ARBs] 
are kidney protective; an ACE inhibitor is the first choice because it is not clear whether 
ARBs are cardioprotective to the level of ACE inhibitors. ACE inhibitor should be used even 
if the patient is not hypertensive and regardless of the level of proteinuria. ACE inhibitors 
slow progression even in those with a low grade of proteinuria. Although the greatest 
benefit is in those with heavy proteinuria. Measures that may increase ACE inhibitor kidney 
protection include a low salt, reduced-protein diet, diuretic therapy, the low BP goal and 
statin therapy. ACE inhibitors are antiproteinuric, even in inflammatory glomerulonephritis. 
ACE inhibitor should be continued even if GFR decline to stage 4 CKD [15 to 29 ml/min 
1.73 m2]. To prevent hyperkalemia, dietary potassium restriction, and the concomitant use of 
a loop diuretic and sodium bicarbonate may be needed. Advancing the ACE inhibitor dose 
to tolerance may increase its antiproteinuric effect and decrease the likeihood of aldosterone 
escape (increasing plasma aldosterone levels during stable ACE inhibitor therapy), which 
may diminish the ACE inhibitor reno-protection. In addition to lowering the 
intraglomerular pressure, experimental studies suggest that the beneficial effect of ACE 
inhibitors may also be related to a number of other factors: 
• Angiotensin II is a growth factor; therefore, diminishing its production may minimize 
glomerular hypertrophy which, by decreasing the capillary radius, can reduce the 
tension on the glomerular capillary wall (Fogo, 2000). 
• Angiotensin II, either directly or via increased glomerular pressure, can enhance the 
release of extracellular matrix and collagen from mesangial and tubular cells, thereby 
promoting both glomerular and tubulointerstitial fibrosis (Boffa et al., 2003). This effect 
is mediated at least in part by enhanced release of transforming growth factor-beta, 
matrix proteins, platelet-derived growth factors, and plasminogen activator inhibitor-I. 
Administration of an ACE inhibitor and/or angiotensin II receptor blocker decreases 
cytokine release, due most likely to a fall in glomerular pressure and/or reversal of the 
direct action of angiotensin II. 
The ability of ACE inhibitors and/or angiotensin II receptor blockers to block the profibrotic 
effect of angiotensin II may be particularly due to their effect to decrease transforming 
growth factor-beta and plasminogen activator inhibitor-I levels (among others), and/or 
increase hepatocyte growth factor concentrations. Due to these effects, ACE inhibitors and 
angiotensin II receptor blockers may help reverse renal sclerosis, as observed in multiple 
animal models of progressive kidney dysfunction (Remuzzi et al., 2002). 
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• An ACE inhibitor may directly improve the size selective properties of the glomerulus, 
thereby preventing the accumulation of macromolecules in the mesangium and a 
secondary increase in mesangial matrix production (Remuzzi et al., 1990). Whether this 
effect is related to or is independent of the associated reduction in intraglomerular 
pressure is not clear. 
• Inhibition of angiotensin II production via ACE inhibition also lowers the release of 
aldosterone.  
• Due to decreased degradation, ACE inhibitors increase bradykinin concentrations, 
which may ameliorate renal tubulointerstitial fibrosis. Support for this was provided by 
an animal model in which unilateral ureteral obstruction-induced interstitial fibrosis 
was significantly increased in bradykinin B2 receptor knockout mice (Schanstra et al., 
2002). Bradykinin may dampen fibrosis by increasing extracellular matrix degradation 
via enhanced metalloproteinase-2 and other enzymatic activity. A similar benefit by this 
mechanism would not be expected with an angiotensin II receptor blocker, which does 
not increase bradykinin levels. 
9.4 Angiotensin II receptor blockers 
The renoprotective effectiveness of angiotensin II receptor blockers (ARBs) has been best 
described in type 2 diabetic nephropathy. It seems likely that they will have a similar 
renoprotective effect as ACE inhibitors in nondiabetic CKD, but supportive data are limited 
(Lee et al., 2006). Studies in humans have found that ARBs are as effective as ACE inhibitors 
in reducing protein excretion in patients with CKD (Hilgers & Mann, 2002). In a 2008 meta-
analysis of randomized trials (mostly small), the reduction in proteinuria at 5 to 12 months 
was similar with ARBs and ACE inhibitors (ratio of means 1.08, 95% CI 0.96-1.22). In 
addition, the reduction in proteinuria with ARBs was significantly greater than that with 
amlodipine (ratio of means 0.62, 95% CI 0.55-0.70). As with ACE inhibition, there appears to 
be a dose effect, with greater reduction of proteinuria at higher (even supramaximal) doses 
in both nondiabetic and diabetic patients. In the SMART trial, for example, 269 patients with 
proteinuria greater than 1 g/day, despite seven weeks of the maximum approved dose of 
candesartan (16 mg/day) were randomly assigned to candesartan at a dose of 16, 64, or 128 
mg/day. Patients who received 128 mg/day had a significantly greater reduction in 
proteinuria at 30 weeks compared to those who received 16 mg/day (mean difference in 
percent change of proteinuria of 33 percent). The blood pressure was not different between 
groups. Although hyperkalemia required the withdrawal of 11 patients from the trial, there 
was no difference in the incidence of hyperkalemia between groups. Further studies of the 
efficacy, safety, and cost are required before such high dose therapy can be recommended. 
9.4.1 ACE inhibitors plus ARBs 
The reduction in proteinuria appears to be greater when ACE inhibitors are used in 
combination with ARBs than with either drug alone. However, it has not been proven that 
combination therapy improves renal outcomes, and adverse effects are more common. 
9.4.2 ARB plus aliskiren 
The first effective oral direct renin inhibitor, aliskiren, was approved by the United States 
Food and Drug Administration in March 2007. Aliskiren lowers blood pressure to a degree 
comparable to most other agents. In the AVOID trial, aliskiren plus losartan was associated 
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with a significant 20 percent greater reduction in proteinuria compared to losartan alone, in 
the absence of a significantly greater effect on blood pressure (Parving et al., 2008). The role 
of aliskiren in preventing progression of CKD is not yet known (Ingelfinger, 2008). 
9.5 Control protein intake 
In a variety of animal models (such as subtotal nephrectomy and diabetic nephropathy), 
lowering protein intake protects against the development of glomerular scarring (called 
glomerulosclerosis). This effect is mediated, in part, by changes in glomerular arteriolar 
resistance, leading to a reduction in intraglomerular pressure and decreased glomerular 
hypertrophy. 
Studies in humans indicate that an increase in the GFR can be induced by animal protein 
and by amino acid mixtures; in comparison, vegetable protein and egg whites alone produce 
little or no effect. Why the latter sources of protein have little hemodynamic activity is not 
clear, but lower concentrations of the amino acids that cause renal vasodilatation (such as 
glycine and alanine) and lesser stimulation of vasodilator prostaglandins may be involved. 
Enhanced secretion of glucagons, a direct renal vasodilator, may be a mediator of protein-
induced hyper filtration (King & Levey, 1993). A high protein diet also increases the release 
of at least two other hormones that can raise the GFR, including insulin-like growth factor I 
(IGF-I) and kinins. IGF-1 is a direct renal vasodilator that can increase both renal blood flow 
and the GFR. In addition to a possible role in protein-induced hyperfiltration, IGF-1 may 
play an important role in the hyperfiltration and glomerular hypertrophy observed in type 1 
diabetes mellitus. The renin-angiotensin system may also modulate the effect of protein on 
glomerular filtration. Angiotensin II leads to a preferential increase in efferent arteriolar 
resistance, causing an increase in intraglomerular pressure and hyperfiltration. Lowering 
angiotensin II production induces efferent dilatation, which decreases intraglomerular 
pressure and perhaps the GFR. However, there are conflicting data on the effect of a low 
protein diet on renal renin release. Both a reduction in renin gene expression (which could 
contribute to the protective effect of a low protein diet in renal disease) and an increase in 
gene expression have been described. 
Intrarenal mechanisms, including tubuloglomerular feedback, may contribute to protein-
induced hyper filtration (Woods, 1993). An increase in the filtered load of amino acids may 
enhance proximal sodium reabsorption via sodium-amino acid cotransporters in the 
proximal tubule. The ensuing decrease in sodium chloride delivery to the macula densa may 
then activate tubuloglomerular feedback, leading to an elevation in GFR in an appropriate 
attempt to restore macula densa delivery to normal.  
Multiple well-designed randomized controlled human trials have evaluated both the 
efficacy and safety of protein restriction in patients with progressive CKD and reducing 
dietary protein intake from the usual level of about 1 to 1.5g/kg ideal weight per day, to 
about 0.6 to 0.8 g/kg per day slows GFR decline in those with proteinuria of more than 1gm. 
It is generally well tolerated and does not lead to malnutrition in patients with CKD 
provided caloric goals are met, dietary protein is of high biologic value, and metabolic 
acidosis is avoided. Dietary protein intake should be monitored periodically by urine urea 
excretion in 24 hour urine collections. In nutrient balance, urine urea nitrogen of 8.0g/day 
represents a protein intake of 50g/day, which is the target for a 70kg person. If the dietary 
goals are generally being met, 24-hour urine testing every 4 to 6 months is sufficient, 
otherwise, testing at 2- to 3-month intervals is recommended. 
Therefore, we suggest the use a low protein diet (0.6 to 0.8 g/kg per day) in select 
predialysis patients who are highly motivated to follow such a diet. However, the adoption 
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of this diet should NOT preclude the initiation of dialysis in patients with severe CKD, if 
indicated.  
9.6 Restrict salt intake 
High salt intake e.g NaCl 200mmol/day, sodium 4.6g/day, NaCl 11.7g/day, can completely 
override the antiproteinuric effects of ACE inhibitors, ARBs, or NDHCCBs. Also, a high salt 
diet can activate the tissue renin angiogenesis aldosterone system, inducing renal and 
myocardial fibrosis, even though the circulating RAS is suppressed. The recommended 
NaCl intake in CKD is about 80 to 120mmol/day [2 to 3g Na, 4.6 to 6.9g NaCl]. Salt intake 
should be monitored periodically by 24-hour urine collection. Those achieving their NaCl 
goal have 80 to 120mmol Na in their 24-hour urine collection because dietary NaCl is 
excreted almost entirely in urine, unless there are abnormal non-renal NaCl losses.  
9.7 Diuretic therapy 
Diuretic therapy improves BP control and proteinuria in those treated with ACE inhibitors, or 
ARBs. Nevertheless, the ideal is to avoid a diuretic, if possible, because of its multiple 
metabolic dysfunctions, especially induction of diabetes mellitus and stimulation of the RAS.  
9.8 Control blood lipids 
There is indirect evidence of beneficial effects of statins on vessel stiffening and endothelial 
function in patients with CKD. Once renal injury has occurred, the yearly decline in GFR 
may be accelerated and perpetuated by dyslipidemia. However, this effect has been derived 
from post-hoc analyses, which are limited by unmeasured confounders that are closely 
correlated to dyslipidemia. If real, this effect is fairly modest. 
Although statins have demonstrated cardiovascular benefits and result in improved 
cardiovascular outcomes in patients without CKD, the effect of statins on primary 
cardiovascular outcomes in patients with ESRD or less severe renal insufficiency is 
uncertain. Among dialysis patients, both the 4-D and AURORA trials found NO difference 
between statin therapy and placebo with respect to cardiovascular death, nonfatal 
myocardial infarction, and stroke despite significant lipid-lowering. However, the results 
from 4-D and AURORA should NOT be extrapolated to patients with CKD not on dialysis. 
There are meta-analyses and post-hoc analyses of randomized trials that have reported 
decreased all-cause and cardiovascularity mortality with statins.  
If administered, patients with CKD should be treated with the lowest dose of statin that 
reduces the LDL-C to less than 100 mg/dl (2.6 mmol/l). However, more aggressive LDL-
lowering to less than 70 mg/dl (1.8 mmol/l) is a reasonable option, if the additional therapy 
does not impose undue burdens from side effects or cost. 
With respect to adverse effects, good side effect profiles with statins have been reported 
patients with CKD, dialysis patients, renal transplant recipients. However, accurate 
estimates of the risk of adverse events (especially myopathy) are not available in patients 
with ESRD or moderate to severe chronic renal insufficiency, since the existing clinical trials 
with statins in these patients have been quite small.  
9.9 Smoking cessation 
Smoking cessation should be encouraged, with smoking stoppage being associated with a 
reduced rate of progression of CKD. In an increasing number of studies, smoking also appears 
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to correlate with an enhanced risk of developing kidney disease (primarily nephrosclerosis) as 
well as increasing the rate of progression among those with existing CKD. 
9.10 Avoidance of administration of nephrotoxic drugs 
The administration of drugs or diagnostic agents that adversely affect renal function are a 
frequent cause of worsening renal function. Among patients with CKD, common offenders 
include aminoglycoside antibiotics (particularly with unadjusted doses), nonsteroidal 
antiinflammatory drugs, and radiographic contrast material, particularly in diabetics. The 
administration of such drugs should, therefore, be avoided or used with caution in patients 
with underlying CKD.  
Certain drugs also interfere with either creatinine secretion or the assay used to measure the 
serum creatinine. These include cimetidine, trimethoprim, cefoxitin, and flucytosine. In 
these settings, there will be no change in GFR; the clinical clue that this has occurred is the 
absence of a concurrent elevation in the blood urea nitrogen (BUN).  
9.11 Reduce obesity 
Obesity is associated with multiple other conditions that are known to cause compromised 
renal function, including hypertension, diabetes, and the metabolic syndrome. However, 
data from the Framingham Offspring Study, the Hypertension Detection and Follow-Up 
Program, and the Multiphasic Health Testing Services Program suggest that obesity may be 
independently associated with the risk of developing CKD. Focal glomerulosclerosis and 
obesity-related glomerulopathy (glomerular enlargement and mesangial expansion) with 
associated proteinuria have been described in patients with severe obesity. Obesity-related 
glomerulopathy may be reversible with weight loss.  
9.12 Correction of anemia 
The anemia of CKD is, in most patients, normocytic and normochromic, and is due 
primarily to reduced production of erythropoietin by the kidney (a presumed reflection of 
the reduction in functioning renal mass), and to shortened red cell survival. Anemia is a 
common feature in many patients with CKD who do not yet require dialysis, with anemia 
becoming increasingly common as GFRs decline below 60 ml/min per 1.73 m2, particularly 
among diabetics. As an example, based upon over 15,000 participants in the NHANES 
survey, the prevalence of anemia (Hbg <12 g/dl in men and <11 g/dl in women) increased 
from 1 percent at an eGFR of 60 ml/min per 1.73 m2 to 9 percent at an eGFR of 30 ml/min 
per 1.73 m2 and to 33 to 67 percent at an eGFR of 15 ml/min per 1.73 m2 (Astor et al., 2002).  
As stated in the 2006 K/DOQI Guidelines, the evaluation of anemia in those with CKD 
should begin when the Hgb level is less than 12 g/dl in females, and Hgb levels of less than 
13.5 g/dl in adult males . These levels are based on the Hgb levels below the fifth percentile 
for the adult general population as noted in the NHANES database.  
The anemia observed with CKD is largely diagnosed by excluding non-renal causes of anemia 
in the patient with a suitably decreased GFR. The evaluation of patients should, therefore, 
include red blood cell indices, absolute reticulocyte count, serum iron, total iron binding 
capacity, percent transferrin saturation, serum ferritin, white blood cell count and differential, 
platelet count, and testing for blood in stool. The content of hemoglobin in reticulocytes can 
also be assessed. This work-up should be performed prior to administering epoietin alfa (EPO) 
or darbepoietin alfa therapy. The dialysis patient is in a state of continuous iron loss from 
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gastrointestinal bleeding, blood drawing, and/or, most important with hemodialysis, the 
dialysis treatment itself. Hemodialysis patients lose an average of 2 g of iron per year. Thus, 
iron deficiency will develop in virtually all dialysis patients receiving EPO or darbepoetin 
alfa unless supplemental iron therapy is given orally or intravenously. An important issue in 
the diagnosis of iron deficiency in the patient with CKD or ESRD is that the laboratory criteria 
are markedly different from those in patients with relatively normal renal function. 
Absolute iron deficiency is likely to be present in patients with ESRD when: 
• The percent transferrin saturation (plasma iron divided by total iron binding capacity x 
100, TSAT) falls below 20 percent 
• The serum ferritin concentration is less than 100 ng/ml among predialysis and 
peritoneal dialysis patients or is less than 200 ng/ml among hemodialysis patients. This 
difference in the serum ferritin level is based upon accumulating evidence in 
hemodialysis patients that the maintenance of ferritin levels above 200 ng/ml is 
associated with decreased erythropoietin requirements. 
In addition to absolute iron deficiency, it is now recognized that dialysis patients may have 
functional iron deficiency. This is characterized by the presence of adequate iron stores as 
defined by conventional criteria, but an inability to sufficiently mobilize this iron from the 
liver and other storage sites to adequately support erythropoiesis with the administration of 
erythrocyte stimulating agents (ESA).  
Functional iron deficiency, which usually responds somewhat to iron therapy, must be 
distinguished from inflammatory iron block, which usually does not. Inflammatory iron 
block occurs among patients with refractory anemia due largely to an underlying 
inflammatory state. Both functional deficiency and inflammatory block are associated with 
transferrin saturation =20 percent and elevated ferritin level (between 100 to 800 ng/ml or 
even higher). The response to EPO and/or parenteral iron may help distinguish between 
functional iron deficiency and inflammatory block.  
With increasing doses of ESA, ferritin levels may decrease in patients with functional 
deficiency but not with inflammatory iron block. 
Inflammatory block is most likely present if the weekly administration of intravenous iron 
(50 to 125 mg) for up to 8 to 10 doses fails to result in increased erythropoiesis; instead, this 
course of iron therapy typically results in a progressive increase in ferritin concentration. 
Among patients with inflammatory block, further intravenous iron should not be given 
until the inflammatory condition has resolved. This is thought to be particularly important 
in patients with active, ongoing infections. 
By comparison, among patients with functional iron deficiency, additional intravenous iron 
(in association with an increase in EPO dose) can be effective in increasing Hgb levels, at 
least over the short-term.  
Serial evaluation of iron indices is necessary for the early detection of iron deficiency on 
dialysis once therapy with EPO or darbepoetin alfa is initiated. Serum ferritin levels and the 
percent transferrin saturation should be measured at baseline and then periodically thereafter. 
In patients with adequate iron stores who are on maintenance oral or intravenous iron, 
monitoring every three months is probably adequate, especially after the first few months 
when iron stores are most likely to become depleted. By comparison, monitoring every one to 
two months is recommended in patients just starting EPO therapy or in whom the dose has 
been increased, in those with marginal iron status, or in those with declining serum ferritin or 
TSAT levels. A reduction in serum ferritin can be expected during the first few months after 
the initiation of EPO as iron is mobilized from iron stores and used for red cell production. 
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Prior to initiation of treatment with erythropoietic stimulating agents (ESA), we recommend 
the administration of iron therapy among hemodialysis patients with absolute iron 
deficiency and anemia. This is principally because ESA therapy requires significant amounts 
of supplemental iron for effective erythropoiesis. Although normal body stores of iron are 
800 to 1000 mg, approximately 1000 mg is required among hemodialysis patients to raise 
hemoglobin levels from approximately 8 g/dl to 11 to 12 g/dl with the initiation of ESA 
therapy. After target hemoglobin levels are achieved, approximately 500 mg of iron is 
required every three months to maintain target levels with ESA therapy. 
Among those with percent transferrin saturation =20 percent and ferritin between 200 and 
500 ng/ml, we administer iron therapy prior to the use of ESAs if an underlying infection 
has been excluded. We do not routinely administer intravenous iron without an ESA to 
patients with ferritin levels above 500 ng/ml and anemia, although each patient should be 
individually assessed. 
The most common cause of resistance to ESA is iron deficiency, which can be present at the 
time of initiation of ESA treatment or can develop as the result of exhaustion of iron stores 
due to the increase in erythropoiesis caused by ESA treatment. As shown in numerous 
observational and prospective studies, the administration of iron to obtain adequate iron 
stores increases hemoglobin levels in patients who are not on ESA treatment, as well as 
those who are, and lowers ESA doses. 
If iron indices indicate absolute (transferrin saturation <20 percent and serum ferritin <200 
ng/mL) or functional iron deficiency (transferrin saturation <20 percent and serum ferritin 
>200 ng/ml in the setting of ESA therapy), a sufficient amount of iron to correct the iron 
deficiency should be administered to raise the transferrin saturation above at least 20 to 25 
percent and serum ferritin level above 200 ng/ml, we suggest administering one of the 
following regimens:   
• 125 mg of sodium ferric gluconate complex in sucrose can be given at each consecutive 
hemodialysis treatment for a total of eight doses (1000 mg in total). 
 OR 
• 100 mg iron sucrose can be given at each consecutive hemodialysis treatment for a total 
of 10 doses (1000 mg in total). 
Repeat the initial loading regimen if the transferrin saturation remains below 20 percent, the 
hemoglobin level does not increase to the target level, or the serum ferritin level remains 
below 200 ng/ml. 
Our goal with any loading regimen is to increase hemoglobin levels and raise the transferrin 
saturation above at least 20 to 25 percent and serum ferritin level above 200 ng/mL, while 
not increasing the transferrin saturation above 50 percent or the serum ferritin level above 
500 ng/ml. 
Among hemodialysis patients, use of parenteral iron rather than oral iron therapy is 
recommended . The different parenteral preparations of iron available in the United States 
are iron dextran, sodium ferric gluconate complex in sucrose, and iron sucrose. These 
preparations are largely equivalent in efficacy. However, sodium ferric gluconate complex 
in sucrose and iron sucrose are much safer than iron dextran, which is associated with a 
significant risk of anaphylaxis. Iron replete patients are characterized by transferrin 
saturation levels between 20 to 50 percent and serum ferritin levels between 200 to 500 
mg/l. Among such patients receiving erythropoietin stimulating agents, weekly 
administration of parenteral iron is sufficient to maintain Hgb. 
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As previously mentioned, the anemia of CKD, if left untreated, can result in deterioration in 
cardiac function, and decreased cognition and mental acuity. It can also be accompanied by 
debilitating symptoms, such as fatigue, weakness, lethargy, anorexia, and sleep 
disturbances. In addition, anemic patients commonly lack the stamina needed to perform 
normal daily activities or to work. 
Furthermore, anemia in patients with CKD is also associated with an increased risk of 
morbidity and mortality principally due to cardiac disease and stroke, and with an increased 
risk of hospitalization, hospital length of stay, and mortality in patients with predialysis CKD.  
9.12.1 Administration of erythropoiesis-stimulating agents 
Correction of anemia with erythropoiesis-stimulating agents is associated with some clinical 
benefits. These include improvements in quality of life, increased energy levels, greater 
capacity for work and exercise, restored sexual function, improved appetite and 
participation in social activities, as well as reduced depression and fatigue. 
The erythropoietin deficiency evident in patients with CKD can be corrected by the 
exogenous administration of erythropoiesis-stimulating agents. Two such agents are 
currently available in the United States: 
• Epoetin alfa (recombinant human erythropoietin)  
• Darbepoetin alfa, a unique molecule that stimulates erythropoiesis with a longer half-
life than rHuEPO 
9.12.2 Epoetin alfa (recombinant human erythropoietin [rHuEPO] 
Several general principles govern the administration of recombinant human EPO  
• The response to EPO is dose-dependent, but varies greatly among patients. 
• The response is dependent on the route of administration (intravenous versus 
subcutaneous) and the frequency of administration. With subcutaneous administration, 
frequency is not as important as with the intravenous route.  Response is less 
dependent on route of administration for darbepoetin alfa than for epoetin. 
• The response may be limited by low iron stores, bone marrow fibrosis, infection, 
inflammation, inadequate dialysis, and other conditions. 
• Hypertension may complicate therapy, particularly if the hemoglobin is raised quickly. 
This is primarily limited to patients undergoing dialysis. We recommend that target 
hemoglobin levels in dialysis patients treated with EPO or darbepoetin alfa should be 
maintained between 10 and 12 g/dl. In addition, the Hgb target should NOT exceed 13 
g/dl.  
The vast majority of cases of recombinant human erythropoietin (EPO) - related acquired 
pure red cell aplasia (PRCA) have occurred in patients treated with a particular epoetin 
alfa product. The underlying cause may be organic compounds (leached by polysorbate 
from uncoated rubber stoppers in prefilled syringes) that are acting as adjuvants, resulting 
in anti-EPO antibody development. Virtually all reported cases of anti-EPO antibody 
mediated PRCA have occurred in patients with chronic kidney disease who have received 
the drug subcutaneously. EPO-induced PRCA should be considered in the patient with 
significant anemia who has been treated with EPO for at least three to four weeks, and has 
previously responded to treatment with EPO. The condition is characterized by a sudden 
decline in hemoglobin level despite continued use of EPO, markedly reduced reticulocyte 
count, and normal white blood cell (WBC) and platelet counts. To definitively diagnose 
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EPO-induced PRCA, a bone marrow aspirate and evaluation for the presence of neutralizing 
anti-EPO antibodies should be performed. The bone marrow reveals severe erythroid 
hypoplasia, with less than five percent red blood cell precursors, and there may be evidence 
of a block in the maturation of erythroid precursors. Platelet and white cell precursors are 
entirely normal. Anti-EPO antibodies are detected by radioimmunoprecipitation assay 
(RIPA), enzyme linked immunosorbent assays (ELISA), or other assay, as available. 
Cessation of all erythropoietic stimulating agents with NOT switching to an alternative EPO 
product or to darbepoetin alfa in patients with PRCA is recommended. Patients should be 
transfused for symptomatic anemia.  
Given that spontaneous remissions after cessation of EPO therapy are rare, the 
administration of immunosuppressive therapy in most patients is recommended. Initial 
therapy consisting of prednisone (1.0 mg/kg per day) plus oral cyclophosphamide (50 to 
100 mg per day) for a maximum of three to four months. A reasonable alternative for first-
line therapy is cyclosporine alone at a dose of 200 mg daily (or 100 mg twice daily) for a 
maximum of three to four months. Patients who do not respond to initial treatment with 
either oral cyclophosphamide plus prednisone or with cyclosporine alone may be 
subsequently treated with the other regimen. 
9.12.3 Dose of EPO 
The initial dose of EPO should vary based upon the baseline hemoglobin level, overall 
clinical setting, mode of administration, and the target hemoglobin level. A large number of 
studies have found that there is wide interpatient variability, as the dose of EPO required to 
reach hemoglobin levels above 11 g/dl among hemodialysis patients ranges from less than 
50 to more than 300 U/kg three times per week. 
In general, at a starting dose of 100 U/kg given intravenously three times per week, 90 
percent of patients will attain a hemoglobin level of 11 to 12 g/dl, compared to 70 percent 
who will reach this level with 50 U/kg given intravenously three times per week. The logic 
of starting with the higher dose and then titrating down is that a month of therapy may be 
wasted on the nonresponders if the lower dose is used initially. In addition, titrating up 
from a smaller initial dose allows the hematocrit to rise more smoothly and more 
economically than with the titrate down approach. 
In addition, numerous studies have found that intravenous therapy may also require, on 
average, approximately 30 percent more EPO than with the subcutaneous route. Thus, if 
subcutaneous doses are given, an initial dose for adults is 80 to 120 U/kg per week 
(typically 6000 U/week) given in one to three doses. 
9.12.4 Dosage adjustments 
In general, to attain hemoglobin levels of 11 g/dl or higher, a dose increase of 25 percent 
would be appropriate after four weeks if initial dosing levels do not result in a rate of increase 
in the hemoglobin of approximately 0.3 to 0.5 g/dl per week. Patients with hemoglobin levels 
that are increasing at this rate generally do not need adjustments in the EPO dose. Once the 
desired hemoglobin level is reached, smaller changes in the EPO dose, either titrating up or 
down, are usually satisfactory to maintain desired levels. Changing the dose of EPO more than 
once over a two- to four-week period is unnecessary in most instances. 
Some patients respond to the administration of EPO with a marked acceleration in 
hemoglobin values. Among those with increases in hemoglobin of greater than 2.5 to 3 g/dl 
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per month, the EPO dose should be reduced by at least 25 percent. Some clinicians 
recommend holding EPO for a short period of time (i.e., one week) before resuming 
treatment at the reduced dosing level if the hemoglobin exceeds the target value, while 
others recommend that EPO doses not be held but instead be reduced in dose. For 
hemodialysis patients in whom EPO administration has been initiated or the dose has 
recently changed, the hemoglobin should be measured once per week to adequately assess 
the response; by comparison, the hemoglobin of patients with stable hemoglobin levels and 
EPO dose can be assessed every two to four weeks, although in many dialysis facilities 
weekly hemoglobin levels are commonly obtained. 
9.12.5 Hyporesponsivess to EPO 
Some patients are relatively resistant to EPO and require large doses. This may be an 
important clinical observation since a poor response to EPO therapy may be associated with 
increased mortality. Higher doses of EPO have also been associated with an increased 
mortality, an effect that persists after adjustment for the usually lower hematocrit in such 
patients A large EPO requirement is defined as either the requirement of excessive doses 
during initiation of therapy, or inability to achieve or maintain target Hgb levels despite the 
large dose in the iron-replete patient. Different guidelines have suggested different definitions: 
• 450 U/kg per week intravenous EPO or 300 U/kg per week subcutaneous EPO, per 
K/DOQI (NKF-DOQI, 2001). 
• 300 U/kg per week of EPO (approximately 20,000 U/week) and 1.5 mcg/kg per week 
of darbepoetin alfa (approximately 100 mcg/week), per the revised European 
Guidelines (Locatelli et al., 2004). 
The most common cause of resistance to EPO is absolute iron deficiency which may be due 
to external blood losses and/or exhaustion of iron stores due to an increase in erythropoiesis 
caused by EPO treatment. Additional causes include the following: 
• Bone disease due to secondary hyperparathyroidism;  
• Occult malignancy and unsuspected hematologic disorders  
• Multiple myeloma/myelofibrosis/myelodysplastic syndrome. 
• Chronic inflammation (with inhibition possibly due to enhanced cytokine production)  
• Although now rare, the accumulation of aluminum in bone. 
• Hemoglobinopathies, as patients with sickle cell disease or trait may have an 
inadequate response to the administration of EPO. 
• The administration of angiotensin converting enzyme inhibitors and/or angiotensin II 
receptor antagonists.  
• Development of pure red cell aplasia associated with the presence of neutralizing anti-
erythropoietin antibodies in patients treated with particular brands of EPO by the 
subcutaneous route. 
• Presence of HIV infection. 
9.12.6 Darbepoetin alfa 
Darbepoetin alfa is biochemically distinct from rHuEPO. It contains up to 22 sialic acid 
molecules (compared with a maximum of 14 for rHuEPO), giving it higher potency and an 
approximately three times longer half life than that of rHuEPO (25.3 versus 8.5 hours) 
following intravenous administration, and.approximately twofold longer than that of 
subcutaneously administered rHuEPO (Macdougall et al., 1999). 
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Clinical studies performed in rHuEPO-naive patients (defined as patients who had not 
received rHuEPO within 12 weeks) confirmed that darbepoetin alfa corrects anemia in 
patients with CKD who have not previously been exposed to hematopoietic stimulators. 
Darbepoetin alfa, compared with rHuEPO, controls hemoglobin (Hb) with an extended 
dosing interval. In patients with CKD who are not on dialysis, subcutaneous darbepoetin 
alfa administered once weekly at an initial dose of 0.45 µg/kg or once every two weeks at a 
median dose of 60 µg achieved target Hb concentrations in 93 to 97 percent of patients in a 
median time of five to seven weeks (Locatelli et al., 2001). As with rHuEPO, darbepoetin 
alfa has beneficial effects on quality of life via its ability to correct renal anemia. Interim data 
from a United States study performed in 48 evaluable rHuEPO-naive patients with CKD 
revealed improvements in 20 of the 22 different measures of health-related quality of life 
after 16 weeks of treatment with darbepoetin alfa (Bahman et al., 2002). Over the same 
period, there was a mean increase in Hb levels of 3.3 g/dl. Several large trials have 
confirmed that patients stabilized on either subcutaneous or intravenous rHuEPO can be 
successfully switched to darbepoetin alfa given at extended dosing intervals of once weekly 
or once every two weeks, with maintenance of a constant Hgb (mean change of –0.08 to 0.16 
g/dl) after 28 to 36 weeks of treatment. 
9.12.7 Continuous Erythropoiesis Receptor Activator (C.E.R.A) 
Alternative bioengineering techniques to prolong the half life of EPO further resulted in the 
development of C.E.R.A., which is a pegylated derivative of epoetin beta with an 
elimination half-life of around 130 hours when it is administered either intravenously or 
subcutaneously. Phase III studies suggested that many patients are able to maintain with 
once-monthly administration of C.E.R.A., and a superiority [PATRONUS] suggested greater 
efficacy with this frequency of administration compared with once monthly dosing of 
darbepoetin alfa when it is administered intravenously to hemodialysis patients. 
9.12.8 Epomimetics 
The discovery of a drug that can mimic the action of erythropoietin is another method for 
eliminating the need for recombinant EPO in renal failure (Vadas et al., 2008). Evidence in 
support of this possibility was provided by a study in which a number of short peptides 
were evaluated as possible agonists of the EPO receptor. Peptides whose sequence matched 
a minimum consensus sequence of only 14 amino acids bound to and activated the EPO 
receptor. This observation provides strong experimental evidence that the EPO-EPO 
receptor complex requires only a small number of contact points for full effect. 
Hematide is a synthetic peptide-based ESA with an amino acid sequence that is unrelated to 
erythropoietin. It is currently undergoing evaluation in clinical trials. 
9.13 Management of  hyperparathyroidism 
The treatment of secondary hyperparathyroidism in CKD has evolved based upon new 
insights into the pathogenesis and clinical features of this disorder, the recognition that 
abnormal calcium and phosphate homeostasis may impact upon morbidity and mortality as 
well as mineral homeostasis, and the development of new therapeutic agents that can 
suppress parathyroid hormone (PTH) without exacerbating hyperphosphatemia and 
causing hypercalcemia. 
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Because of the interdependence of calcium, phosphate, vitamin D and PTH, it is difficult to 
elucidate the primary and proximate causes of parathyroid gland dysfunction in patients 
with CKD. In addition, no single pharmacological intervention is sufficient to completely 
restore disordered calcium and phosphate homeostasis. The medical management of 
secondary hyperparathyroidism in patients with CKD principally involves the use of the 
combination of phosphate binders, active vitamin D analogs, and/or calcimimetics (which 
increase the sensitivity of the CaSR to calcium), with differences in management based in 
part upon the degree of renal dysfunction and whether the patient is on dialysis. 
Kidney failure disrupts systemic calcium and phosphate homeostasis and affects the bone, 
gut, and parathyroid glands. This occurs because of decreased renal excretion of phosphate 
and diminished renal hydroxylation of 25-hydroxyvitamin D to calcitriol (1,25-
dihydroxyvitamin D). 
Circulating calcitriol levels begin to fall when the GFR is less than 40 ml/min (occasionally 
even less than 80 ml/min  and are typically markedly reduced in subjects with end-stage 
renal failure. The loss of functioning renal tissue and physiologic suppression by 
hyperphosphatemia  participate in the decline in calcitriol synthesis. Thus, progressive 
kidney dysfunction results in hyperphosphatemia and calcitriol deficiency. These ultimately 
result in hypocalcemia. These abnormalities directly increase PTH levels via different 
mechanisms. 
The CaSR [calcium-sensing receptor] which is highly expressed in the parathyroid glands, 
permits variations in the serum calcium concentration to be sensed by the parathyroid gland, 
leading to the desired changes in PTH secretion. The fall in serum calcium concentration with 
renal failure, as sensed by the CaSR, is a potent stimulus to the release of PTH. 
There are reductions in calcitriol-regulated calcium absorption in the gut and calcium 
release from bone, both of which promote the development of hypocalcemia; this is a potent 
stimulus to the release of parathyroid hormone (PTH), as previously mentioned. 
Calcitriol acts on the vitamin D receptor (VDR) in the parathyroid gland to suppress PTH 
transcription, but not PTH secretion. The absence of vitamin D also decreases calcium and 
phosphorus absorption in the gastrointestinal tract. The net effect of low vitamin D levels is 
to directly increase PTH production due to removal of the normal suppressive effect of 
calcitriol on the parathyroid glands, and indirectly increase secretion through the 
gastrointestinal mediated hypocalcemic stimulus. 
A decrease in calcitriol levels also lowers the number of vitamin D receptors in the 
parathyroid cells. The lack of calcitriol and the decreased number of receptors may both 
directly promote parathyroid chief cell hyperplasia and nodule formation through potential 
non-genomic effects. 
If the physiologic abnormalities are not corrected, renal bone disease, referred to as renal 
osteodystrophy, will develop. Although frequently asymptomatic, this disorder can result in 
weakness, fractures, bone and muscle pain, and avascular necrosis. These symptoms and 
signs do not generally occur until the patient is undergoing maintenance dialysis. 
There are several forms of renal osteodystrophy, including osteitis fibrosa cystica, 
adynamic bone disease, and osteomalacia. In some patients, there is evidence of more 
than one type, which is called mixed osteodystrophy. Osteitis fibrosa cystica and mixed 
osteodystrophy are largely the direct result of increased PTH levels, while adynamic bone 
disease is a consequence of excessive suppression of the parathyroid gland with current 
therapies. 
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9.14 Chronic kidney disease - mineral and bone disorder (CKD-MBD) 
The 2009 KDIGO practice guidelines were developed to provide recommendations for the 
evaluation and management of chronic kidney disease-mineral and bone disorder (CKD-
MBD) (KDIGO, 2009). The term CKD-MBD was created to describe the syndrome associated 
with mineral, bone, and calcific cardiovascular abnormalities. The guidelines were 
formulated in an attempt to minimize the morbidity and mortality associated with abnormal 
mineral metabolism, abnormal bone process, and extraskeletal calcification. 
Stepped treatment approach in patients with CKD grades 3 through 5 not yet on dialysis 
with PTH levels higher than target level: 
Step 1. Among patients with serum phosphate levels greater than target levels, first 
restricting dietary phosphate intake. Although the optimal limit is unclear, we 
usually limit phosphate intake to 900 mg per day. 
Step 2. Among patients with serum phosphate levels greater than target levels despite 
dietary phosphorus restriction after two to four months, the administration of 
phosphate binders is recommended. The two principal options are calcium and 
non-calcium based phosphate binders: 
• For patients with an initial serum calcium levels less than 9.5 mg/dl (<2.37 mmol/l), a 
calcium containing phosphate binder may be administered as long as hypercalcemia 
does not develop. 
• For patients with an initial serum calcium level greater than than 9.5 mg/dl (<2.37 
mmol/l), we recommend a non-calcium based phosphate binder rather than a calcium-
containing phosphate binder. Either sevelamer or lanthanum carbonate can be given in 
this setting. 
Among predialysis patients with stage 3 to 5 CKD and elevated plasma intact PTH, 
treatment with ergocalciferol be initiated if nutritional vitamin D deficiency exists, as 
demonstrated by a 25(OH)-vitamin D (calcidiol) level of less than 30 ng/ml. After initiating 
treatment, serum calcium and phosphorus should be monitored quarterly, and continued 
need for supplementation with ergocalciferol can be re-evaluated annually. If the serum 
level of corrected total calcium exceeds 10.2 mg/dl (2.54 mmol/l), ergocalciferol therapy 
should be discontinued.  
Step 3. If elevated PTH levels remain despite optimal ergocalciferol and phosphate binder 
therapy over a six-month period, administration of low dose active oral vitamin D 
analog is recommended.  Any one of the available active oral agents (calcitriol, 
alfacalcidol, doxercalciferol, or paricalcitol) may be administered using cost and 
formulary availability as guides. The optimal regimen is not clear. Treatment with a 
vitamin D analog should not be given to predialysis patients with stage 3 to 5 CKD 
with elevated serum phosphate levels. A vitamin D analog should also not be given 
unless the corrected serum total calcium concentration is less than 9.5 mg/dL (<2.37 
mmol/L). In addition, initiation of vitamin D supplementation requires close 
outpatient follow-up to avert severe hypercalcemia, with serum calcium and 
phosphate being measured at least every three months. If the serum level of 
corrected total calcium exceeds 10.2 mg/dl (2.54 mmol/l), ergocalciferol therapy 
and all forms of vitamin D therapy should be discontinued.  
Step 4. Among predialysis patients with secondary hyperparathyroidism that is refractory 
to therapy with vitamin D analogues, calcium supplements, and phosphate binders, 
cinacalcet may be useful. However, the use of cinacalcet in early stages of CKD is 
www.intechopen.com
 
Topics in Renal Biopsy and Pathology 
 
236 
highly controversial. Some experts and the KDIGO working group recommend 
NOT giving cinacalcet given the paucity of data concerning efficacy and safety in 
predialysis patients with CKD (Levin et al., 2008). Alternatively, parathyroidectomy 
could be considered for patients with refractory hyperparathyroidism and 
hypercalcemia not responsive to medical therapy. 
If cinacalcet is administered, however, laboratory values should be monitored closely 
(weekly after starting therapy or change in dose) because of the risk of hypocalcemia and 
elevations of serum phosphate. The initial dose of 30 mg/day should be cautiously titrated 
upwards every two weeks only if the serum calcium level is greater than 8.4 mg/dL (2.1 
mmol/liter) and PTH is higher than the target range. 
Stepped approach to the management of hyperparathyroidism and bone mineral 
abnormalities in dialysis patients: 
Steps 1 and 2   Serum calcium, albumin, phosphate, 25(OH) vitamin D and intact PTH levels 
are measured initially and then on an ongoing basis. The initial focus in managing 
secondary hyperparathyroidism should be the prevention and management of 
hyperphosphatemia. 
As a first step, a dietary restriction of 900 mg/day of phosphorus is appropriate. There 
should be an emphasis on high biologic sources of phosphorus (meats, eggs) and avoidance 
of lower nutritional sources (certain vegetables, colas). 
Serum phosphate and calcium levels are next optimized, which involves treating 
hyperphosphatemia without causing hypercalcemia. This is difficult to achieve with thrice 
weekly hemodialysis. 
We suggest the following interventions based upon serum phosphate and calcium levels. 
• Phosphate <5.5 mg/dl (<1.78 mmol/l) and calcium <9.5 mg/dL (<2.37 mmol/l) — 
Calcium-based phosphate binders should be administered. Daily elemental calcium 
intake from binders to less than 1,500 mg, and total elemental calcium from diet and 
binders to less than 2,000 mg (in the presence of concurrent therapy with active vitamin 
D analogues) is recommended. Either calcium carbonate or calcium acetate can be 
administered. 
• Phosphate <5.5 mg/dl (<1.78 mmol/l) and calcium >9.5 mg/dl (>2.37 mmol/l) — No 
phosphate binder is necessary in most patients.  
• Phosphate >5.5 mg/dl (>1.78 mmol/l) and calcium >9.5 mg/dl (>2.37 mmol/L) — We 
recommend the administration of a non-calcium containing phosphate binder rather 
than calcium containing binders. Either sevelamer or lanthanum can be given. 
• Phosphate >5.5 mg/dl (>1.78 mmol/l) and calcium <9.5 mg/dl (<2.37 mmol/l) —  First 
titrating a calcium-based phosphate binder (up to 1,500 mg of elemental calcium from 
binders alone if there is concurrent use of active vitamin D analogues). If phosphate 
remains above 5.5 mg/dl (>1.78 mmol/l), then add a non-calcium containing phosphate 
binder. 
Step 3. The next step is to decide whether phosphate binder therapy is sufficient or 
whether a calcimimetic or vitamin D analogue should be added. This is based upon 
calcium, phosphate, and PTH levels that are measured when administering optimal 
phosphate binder therapy (as defined in step 2). 
If calcium supplementation and phosphate binders are effective in controlling PTH (ie, level 
between 150 and 300 pg/ml), no additional therapy may be needed. Serial follow up of PTH 
levels should be performed at three month intervals to assess the continued control of disease. 
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If PTH levels remain greater than 300 pg/ml with optimal binder therapy, the choice  
is either cinacalcet or vitamin D analogues. The decision to use vitamin D or cinacalcet as  
the next step, without additional data on outcomes, should be based upon the calcium  
and phosphate levels that are measured when administering optimal phosphate  
binders: 
If the calcium and phosphate levels are both toward the upper limit of target levels, we 
suggest administering cinacalcet. This is because cinacalcet lowers both these parameters, 
while vitamin D therapy has the potential to further increase calcium and phosphorus levels. 
If the calcium level is near or below the lower limit of normal and the phosphate is well 
within the normal range, we suggest the administration of vitamin D, given that 
cinacalcet would further lower the serum calcium. There are no compelling data to use 
intravenous versus oral therapy or one form of vitamin D analogue over the other. Cost and 
patient compliance would be two considerations. 
Based upon this rationale, we initiate cinacalcet in patients with PTH >300 pg/ml and the 
following measured levels of phosphate and calcium when administering optimal 
phosphate binder therapy: 
• Phosphate >5.5 mg/dl (>1.78 mmol/l) and Calcium >8.4 mg/dl (>2.1 mmol/l) 
• Phosphate <5.5 mg/dl (<1.78 mmol/l) and Calcium >9.5 mg/dl (>2.37 mmol/l) 
Since cinacalcet lowers serum calcium levels, it should not be initiated if the serum calcium 
level is less than 8.4 mg/dl (less than 2.1 mmol/l). 
We suggest that a vitamin D analogue would be the initial choice in patients with PTH >300 
pg/ml, and the following measured levels of phosphate and calcium when administering 
optimal phosphate binder therapy: 
• Phosphate <5.5 mg/dl (<1.78 mmol/l) and Calcium <9.5 mg/dl (<2.37 mmol/l) 
Since vitamin D analogues raise serum calcium and phosphate levels, we recommend NOT 
initiating these agents if the serum calcium level is greater than 9.5 mg/dl (>2.37 mmol/l), 
serum phosphate is greater than 5.5 mg/dl (>1.78 mmol/l), or the Ca X P product is greater 
than 55 mg2/dl2. 
Step 4. The final step is to adjust the doses of phosphate binders, active vitamin D, and 
cinacalcet to attempt to attain target values: 
Among patients with inadequate reduction of PTH with initial therapies, serum phosphate 
<5.5 mg/dl (<1.78 mmol/l), and serum calcium <9.5 mg/dL (<2.37 mmol/l), we suggest 
adding active vitamin D among those already receiving cenacle 
Among patients with inadequate reduction of PTH with initial therapies and serum calcium 
>8.4 mg/dl (>2.1 mmol/l), we suggest adding cinacalcet among those already receiving a 
vitamin D analogue. 
10. Preparation for and initiation of renal replacement therapy 
It is important to identify patients who may eventually require renal replacement therapy 
since adequate preparation can decrease morbidity and perhaps mortality. Early 
identification enables dialysis to be initiated at the optimal time with a functioning chronic 
access and may also permit the recruitment and evaluation of family members for the 
placement of a renal allograft prior to the need for dialysis. In addition, the ability of the 
individual to psychologically accept the requirement of life-long renal replacement therapy 
is often diminished if inadequate time has elapsed between the time of recognition of ESRD 
and the initiation of dialysis. 
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CKD progresses at a variable rate due to differences in the clinical course of the underlying 
diseases (particularly between individuals) and the recognition that the natural history of 
progressive renal disease can be altered by various therapeutic interventions, particularly 
strict blood pressure control with an ACE inhibitor or ARB. As a result, exactly if and when 
a patient may require dialysis or renal transplantation is unclear. In addition, some patients 
refuse renal replacement therapy until the onset of absolute indications, while others desire 
early initiation to avoid the complications of severe chronic kidney disease, such as 
malnutrition. 
10.1 Referral to nephrologists 
Patients with CKD should be referred to a nephrologist early in the course of their disease, 
preferably before the plasma creatinine concentration exceeds 1.2 (106 micromol/l) and 1.5 
mg/dl (133 micromol/l) in women and men, respectively, or the eGFR is less than 60 
ml/min per 1.73 m2. These subspecialists are trained to help counsel the patient in choosing 
the optimal renal replacement therapy and to manage the many issues associated with CKD. 
Lower costs and/or decreased morbidity and mortality may be associated with early 
referral and care by subspecialists. Reasons for later referral may include disease specific 
factors, patient and physician dependent causes, and health care system related factors. Late 
referral to a nephrologist has been associated with higher mortality after the initiation of 
dialysis (Kazmi et al., 2004). 
An equally important component of early identification is institution of renoprotective 
therapy (eg, ACE inhibitor, angiotensin II receptor blocker, and rigorous blood pressure 
control) as early as possible after identifying the presence of progressive chronic kidney 
disease. Protective therapy has the greatest impact if it is initiated before the plasma 
creatinine concentration exceeds 1.2 (106 micromol/l) and 1.5 mg/dl (133 micromol/l) in 
women and men, respectively, or the eGFR is less than 60 ml/min per 1.73m2. At this point, 
most patients have already lost more than one-half of their GFR. Waiting until the disease 
progresses further diminishes the likelihood of a successful response but still should be 
attempted.  
10.2 Choice of renal replacement therapy 
Once it is determined that renal replacement therapy will eventually be required, the patient 
should be counseled to consider the advantages and disadvantages of hemodialysis  
(in-center or at home), peritoneal dialysis (continuous or intermittent modalities), and renal 
transplantation (living or deceased donor). The 2006 K/DOQI guidelines recommend  
that patients with a GFR less than 30 ml/min per 1.73 m2 should be educated concerning 
these issues. 
Kidney transplantation is the treatment of choice for ESRD. A successful kidney transplant 
improves the quality of life and reduces the mortality risk for most patients, when compared 
with maintenance dialysis. To facilitate early transplantation, a 2008 NKF/KDOQI 
conference suggested early education and referral to a transplantation center plus the 
identification of potential living donors. 
However, not all patients are appropriate candidates for a kidney allograft because of 
absolute and/or relative contraindications to this procedure or the subsequent required 
medications. Referral to a transplant program should occur once renal replacement therapy 
is thought to be required within the next year.  
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For these individuals and for those who are suitable transplant recipients but must wait for 
an available kidney, the choice between hemodialysis or peritoneal dialysis is influenced by 
a number of considerations such as availability, convenience, comorbid conditions, home 
situation, age, gender, and the ability to tolerate volume shifts.  
In the United States, the universal availability of renal replacement therapy forces the 
nephrologist to consider its application in every patient in whom it might be indicated. 
However, the patient, particularly the elderly and terminally ill, may refuse dialysis, a 
choice which is assuming more prominence as patients and physicians grapple with the 
increasing use of advance directives, and the laudable goals of death with dignity and life 
with quality. Nevertheless, not all nephrologists are willing to recommend no treatment, 
especially when dialysis facilities are available with no need to ration therapy. These issues 
can be a source of conflict among physicians, patients, and their families.   
10.3 Indications for renal replacement therapy 
The decision to initiate dialysis in a patient with CKD involves the consideration of 
subjective and objective parameters by the physician and the patient. These parameters are 
often modulated by the patient's perception of his or her quality of life and by possible 
anxiety about starting new therapy that is technologically complex. 
There are a number of clinical indications to initiate dialysis in patients with CKD. These 
include: 
• Pericarditis or pleuritis (urgent indication) 
• Progressive uremic encephalopathy or neuropathy, with signs such as confusion, 
asterixis, myoclonus, wrist or foot drop, or, in severe, cases, seizures (urgent indication) 
• A clinically significant bleeding diathesis attributable to uremia (urgent indication) 
• Fluid overload refractory to diuretics 
• Hypertension poorly responsive to antihypertensive medications 
• Persistent metabolic disturbances that are refractory to medical therapy. These  
include hyperkalemia, metabolic acidosis, hypercalcemia, hypocalcemia, and 
hyperphosphatemia. 
• Persistent nausea and vomiting 
• Weight loss or signs of malnutrition 
However, these indications are potentially life-threatening. They occur when the patient has 
very advanced CKD, such as may be observed in those who present with severe uremia and 
have not had prior medical contact. For patients under medical care, delaying initiation of 
dialysis until one or more of these complications is present may put the patient at unnecessary 
jeopardy; dialysis should therefore be initiated well before these indications have developed. 
Patients with CKD should, therefore be closely followed and the GFR estimated.  
11. Cardiovascular disease in patients with chronic kidney disease 
11.1 Introduction 
Cardiovascular disease (CVD) is common in the general population, affecting the majority 
of adults past the age of 60 years. The prevalence of coronary heart disease (CHD) is 
approximately one-third to one-half that of total CVD.  
It is increasingly appreciated that chronic renal dysfunction alone is an independent risk 
factor for the development of CHD, and for more severe coronary heart disease (CHD) 
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(USRDS, 2010). Chronic kidney disease (CKD) is also associated with an adverse effect on 
prognosis from cardiovascular disease. This includes increased mortality after an acute 
coronary syndrome and after percutaneous coronary intervention (PCI) with or without 
stenting. 
Patients on renal replacement therapy appears to be at extraordinary risk for premature death 
due to cardiovascular complications. Although accelerated atherosclerosis may be one 
important cause of the high cardiovascular mortality in this patient group, the CVD pattern is 
atypical in that volume overload and left ventricular hypertrophy (LVH) are very common. In 
addition, the incidence of sudden cardiac death, arrhythmias, hypertension, coronary artery 
disease (CAD), peripheral vascular disease (PVD), and pericarditis is markedly increased, and 
cardiac arrest or arrhythmia is the major cause of cardiovascular death in this patient 
population. CKD patients should therefore be considered in the “highest-risk” group for CVD, 
irrespective of levels of traditional CVD risk factor.  The presence of cardiovascular disease is 
an important predictor of mortality in patients with ESRD, as it accounts for almost 50 percent 
of deaths. Of these, approximately 20 percent can be attributed to the consequences of CAD. 
Patients with varying stages of CKD but who are not yet dialysis-dependent also have a 
markedly increased risk of morbidity and mortality from CVD, including CHD. 
11.2 Epidemiology 
The incidence/prevalence of coronary disease in the dialysis population depends in part 
upon the definition that is used (Herzog, 2003). A confounding issue is that coronary disease 
often presents in atypical fashion in dialysis patients. As a result, the presence of CHD is 
frequently overlooked due to the absence of classic symptoms and/or signs of heart disease. 
Overall, the incidence is much higher than that observed in the general population. 
Approximately 40 percent of incident dialysis patients have ischemic heart disease  
(Cheung et al., 2004), with an annual rate of myocardial infarction and/or angina of 
approximately 10 percent. 
• Almost 40 percent of the 1846 patients enrolled in the HEMO report were noted to have 
ischemic heart disease at study initiation (Cheung et al., 2004). During the mean follow-
up period of 2.8 years, angina and acute myocardial infarction were responsible for 43 
percent of all cardiac hospitalizations, with ischemic heart disease causing 62 percent. 
• Utilizing data from Wave II of the United States Renal Data System (USRDS) Dialysis 
Morbidity and Mortality study, the incidence of an acute coronary syndrome was 2.9 
percent per year among 3374 incident dialysis patients followed for approximately two 
years (Trespalacios et al., 2002). 
• In one Japanese study, the presence of significant occult coronary artery disease using 
coronary angiography (greater than 50 percent stenosis) was found in 16 of 30 
asymptomatic patients (53 percent) initiating renal replacement therapy (Ohtake et al., 
2005). 
Cardiac disease, including coronary artery disease, left ventricular hypertrophy (LVH) and 
heart failure (HF), is common in patients with chronic kidney disease (CKD). LVH appears 
to be increasingly prevalent as the glomerular filtration rate (GFR) declines and with 
increased dialysis vintage. 
• LVH has been found in as many as 30 to 45 percent of patients with chronic kidney 
disease (CKD) not yet on dialysis, with a higher prevalence and more severe LVH in 
those with increasingly lower degrees of renal function (Moran et al., 2008). 
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• Concentric LVH has been documented by echocardiography in 42 percent of patients at 
the start of dialysis and in as many as 75 percent of patients who have been on 
hemodialysis for 10 years (Parfrey & Foley, 1999). 
11.3 Association with traditional and non-traditional risk factors 
Although CKD alone is an independent risk factor for CHD, it is worthwhile to review the 
variety of abnormalities commonly observed in these patients that enhance the overall risk 
of cardiovascular disease (Table 4). 
Traditional cardiovascular risk factors, such as hypertension (which may be accompanied by 
left ventricular hypertrophy), smoking history, diabetes, dyslipidemia and older age, are 
highly prevalent in CKD populations. The number of cardiovascular risk factors appears to 
correlate with the severity of kidney dysfunction. 
Patients with CKD are also more likely to have the metabolic syndrome, which could 
contribute to the increase in cardiovascular risk (Chen et al., 2004). This syndrome is defined 
as some combination of insulin resistance, dyslipidemia, elevated serum glucose, abdominal 
obesity, and hypertension.  
There are additional possible risk factors that are relatively unique to patients with 
moderate to severe CKD. These include retention of uremic toxins, anemia, increased 
calcium intake, abnormalities in bone mineral metabolism, proteinuria, and/or an 
"increased inflammatory-poor nutrition" state. 
The purported link between some of these additional factors and an enhanced risk for CHD 
is uncertain. As an example, studies examining the relationship between coronary artery 
calcification and abnormalities in mineral metabolism (phosphorus, calcium, and 
parathyroid hormone) in patients with moderate to severe CKD have demonstrated 
increased coronary artery calcification, but conflicting data on independent risk factors 
(Dellegrottaglie et al., 2006).  
 
Traditional CVD Risk Factors CKD Related “Nontraditional” CVD Risk Factors 
Older age Type (diagnosis) of CKD 
Male gender Decreased GFR 
White Race Proteinuria  
Hypertension Renin-angiotensin system activity 
Elevated LDL cholesterol Extra-cellular fluid volume overload 
Decreased HDL cholesterol Abnormal Calciam and Phosphorus 
Diabetes mellitus Metabolism 
Tobacco use Dyslipidemia 
Physical inactivity Anemia 
Menopause Malnutrition 
Psychosocial stress Inflammation 
Family history of CVD Infection 
 Thrombogenic fectors 
 Oxidative stress 
 Elevated homocysteine 
 Advanced glycation end-products (AGEs) 
 Uremic toxins 
Table 4. Traditional vs. CKD- related factors associated with an increased risk for CVD. 
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Elevated levels of CRP and asymmetric dimethylarginine were both associated with 
increased risks of all cause and cardiovascular mortality in the Modification of Diet in Renal 
Disease study, after adjustment for known cardiovascular risk factors (Menon et al., 2005; 
Young et al., 2009), though a similar relationship for CRP was not seen in the Irbesartan for 
Diabetic Nephropathy trial. Hyperhomocysteinemia has also been inconsistently associated 
with increased cardiovascular risk. 
Anemia has emerged as an important, independent risk factor for the development and 
progression of LVH and HF in CKD, and of adverse cardiovascular outcomes, including 
mortality. The presence of LVH is important clinically because it is associated with increases 
in the incidence of heart failure, ventricular arrhythmias, death following myocardial 
infarction, decreased LV ejection fraction, sudden cardiac death, aortic root dilation, and a 
cerebrovascular event. 
11.3.1 Inflammation 
The chronic inflammatory milieu of uremia may contribute to vascular calcification. A large 
number of proinflammatory or antiinflammatory substances have been evaluated as 
possible factors underlying this abnormal milieu. These include osteopontin, 
osteoprotegerin and fetuin. Osteopontin (a chemoattractant) concentrations in blood and in 
atherosclerotic plaques are increased in hemodialysis patients compared to age-matched 
healthy controls, and may correlate with aortic calcification score. 
Inflammatory states and chronic kidney disease are also associated with altered levels of 
osteoprotegerin and alpha-2-Heremann Schmitt glycoprotein (AHSG, or human fetuin). 
Both of these factors are considered protective against extraosseous calcification. 
Normal levels of fetuin help clear apoptotic cells, which act as potential niduses for crystal 
formation in medial arterial calcification, by augmenting phagocytosis. In vitro, fetuin 
appears to inhibit the precipitation of hydroxyapatite from supersaturated solutions of 
calcium and phosphate via the formation of a fetuin-mineral complex (FMC), which 
contains calcium phosphate, matrix Gla protein (MGP), fetuin, and other fetuin-like 
compounds. 
Low fetuin levels, which are observed with CKD and other chronic inflammatory states, are 
associated with increased vascular calcification, cardiovascular mortality, and overall 
mortality in some studies of dialysis patients. The sera of dialysis patients with low fetuin 
concentrations also demonstrated impaired capacity to inhibit calcium/phosphate 
precipitation. 
11.3.2 Oxidative and carbonyl stress 
Increased production of cytokines due to oxidative stress is also observed among patients 
with renal failure. Oxidative stress, which occurs when there is an excessive free-radical 
production or low antioxidant level, could be an important condition for the development of 
endothelial dysfunction, inflammation, and atherogenesis. Lower plasmalogen levels, an 
indicator of such stress, have been reported in malnourished and inflamed patients with 
CKD. 
With renal failure, molecules that are not cytokines may also accumulate and provoke an 
inflammatory response. As an example, advanced glycosylated end-products (AGE), which 
result from carbonyl stress, can clearly initiate inflammation in patients with renal failure. 
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11.3.3 Decreased antioxidants 
The oral intake or the level of some antioxidants is lower than normal in both CRF and 
ESRD patients. An acute-phase response is also associated with decreased plasma levels of 
several antioxidants, such as serum vitamin C concentrations. Low serum vitamin C levels 
are in turn associated with increased cardiovascular morbidity and mortality. 
11.3.4 Vascular calcification 
Vascular calcification in patients with CKD, noted radiologically for decades, has been of 
increasing interest within the renal literature. The presence of calcium in the intimal layer 
may be a marker for plaque vulnerable to rupture and is associated with occlusive disease, 
while the presence of calcium in the vessel media may have direct adverse effect on vascular 
distensibility. The reduced vascular compliance may lead to increased pulse pressure, 
reduced coronary perfusion, and abnormal autonomic and endothelial vasomotor function. 
Such overall vascular stiffness may have a profound negative effect upon survival for 
dialysis patients. Risk factors to both types of calcification include excess calcium and 
phosphate, hyperparathyroidism/chronic inflammation and decreased circulating, or 
tissue-bound, inhibitors of the calcification process. Both appear to progress by a series of 
elaborate mechanisms similar to bony ossification and may involve genetic susceptibility or 
gene polymorphisms. 
11.3.5 Chronic kidney disease alone as a risk factor for CHD 
Based upon observational data in patients with CKD due to a variety of systemic and 
kidney-specific diseases, CKD is associated with an increased risk of adverse cardiovascular 
outcomes and is considered a CHD risk equivalent and the risk increases with increasing 
renal dysfunction and/or severity of proteinuria. The presence of both decreased renal 
function and increased proteinuria appears to further enhance the risk of cardiovascular 
disease versus that associated with either alone. 
All patients with the same degree of renal dysfunction also do not have the same risk of 
cardiovascular disease. As an example, the overall risk for a 25 year old nonsmoking man 
with moderate CKD due to IgA nephropathy is not the same as that of a 65 year old man 
with a similar degree of CKD due to IgA but with a long history of smoking, hypertension, 
and elevated serum cholesterol levels. Thus, in addition to the evaluation for the presence of 
CKD, the proper assessment of overall cardiovascular risk requires an adequate assessment 
for the presence and severity of the other major risk factors for cardiovascular disease. 
Therefore, patients with either an estimated GFR that is less than 60 ml/min per 1.73 m2 or 
with proteinuria greater than one gram/day to have sufficient increased cardiovascular risk 
to be considered a CHD risk equivalent. 
11.4 Treatment and prevention of cardiovascular disease  
11.4.1 Therapeutic lifestyle changes  
Therapeutic lifestyle changes are a part of decreasing the risk of adverse cardiovascular 
outcomes in patients with CKD. 
11.4.2 Smoking 
In hemodialysis patients, smoking greatly increases the risk for cardiovascular morbidity 
and mortality. However, unlike that found in the general population, there are no studies 
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showing beneficial cardiovascular outcomes with smoking cessation in dialysis patients. 
Despite this, we recommend that dialysis patients completely stop smoking, given the 
marked benefits of smoking cessation observed in the general population.  
11.4.3 Weight reduction 
In those with normal renal function, obesity is associated with an increased risk for 
cardiovascular disease. By comparison, the benefits of weight reduction in dialysis patients 
are unclear. In contrast, there appears to be a survival advantage in obese dialysis patients. 
The higher mortality risks in dialysis patients with lower body mass indices may be 
attributed to malnutrition. Limited data suggest that increased muscle mass confers greater 
survival advantage than increased fat in the dialysis population. In general, we do not 
currently recommend weight reduction for dialysis patients, although it is reasonable to 
recommend an increase in muscle rather than fat. Weight reduction may be attempted in 
morbidly obese patients. 
11.4.4 Exercise 
Regular exercise has a variety of possible cardiovascular benefits in those with normal renal 
function. By comparison, a paucity of data exists concerning the association between 
cardiovascular benefits, survival, and exercise in dialysis patients. This was examined using 
data for 2507 patients from the Dialysis Morbidity and Mortality Wave 2 study. Decreased 
mortality was associated with patients who exercised two to three and four to five times per 
week. However, for unclear reasons, daily exercise provided no survival benefit. 
11.4.5 Oxidative stress 
A number of studies have demonstrated that hemodialysis patients are, in general, at a state 
of increased oxidative stress, suggesting the possibility that antioxidant therapies may 
improve clinical outcomes. Limited evidence suggests that an attempt to lower oxidative 
stress may improve cardiovascular disease outcomes in ESRD. 
11.4.6 Hyperhomocysteinemia 
Hyperhomocysteinemia is common in patients with ESRD. As observed in those with 
normal kidney function, lowering homocysteine levels does not improve cardiovascular 
outcomes in dialysis patients. Folic acid and B vitamins decrease homocysteine levels in this 
population .Treatment with high doses of folic acid and B vitamins did not improve survival 
or reduce the incidence of vascular disease in patients with advanced CKD or ESRD. This 
was best shown in the double-blind randomized controlled trial Homocysteinemia in 
Kidney and End Stage Renal Disease (HOST), which compared the effect of folic acid (40 
mg/day), pyridoxine (100 mg/day), and vitamin B12 (2 mg/day) versus placebo on 
vascular outcomes in 2056 patients with advanced CKD, including ESRD. At a median 
follow-up of 3.2 years, there was NO difference between the groups in terms of total 
mortality, myocardial infarction, stroke, and amputations. 
11.4.7 Mineral metabolism issues  
Cardiovascular disease in dialysis patients may be due in part to the presence of excess 
vascular calcification, particularly in the form of extensive coronary artery calcification. A 
key question is what drives the development and maintenance, or progression, of such 
abnormal calcification. Abnormalities of mineral metabolism and therapeutic maneuvers 
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aimed at correcting these abnormalities have been implicated as primary underlying 
pathogenic factors. These include hyperphosphatemia, administration of calcium-containing 
oral phosphate binders, elevated parathyroid hormone levels, and (possibly) decreased 
serum vitamin D levels. 
No prospective randomized studies have demonstrated a cardiovascular benefit and/or a 
survival advantage with any of the current therapeutic options, including limiting calcium 
intake, use of non-calcium or calcium-containing phosphate binders, active vitamin 
D therapy, and administration of calcimimetics. However, observational studies have 
shown improved survival in hemodialysis patients treated with active vitamin D analogues. 
Despite the absence of evidence from randomized trials, we generally aim for a calcium x 
phosphate product less than 55 mg2/dL2 using current therapeutic options. However, it is 
possible that even lower levels (<50 mg2/dl2) offer further survival advantage. 
11.4.8 Diabetes mellitus 
Guidelines from the American Heart Association and the American Diabetes Association 
recommended  optional glycemic control, reaching blood pressure target levels and lipids 
monitoring (with subsequent dysplipidemia treatment). In CKD patients with diabetes, 
CVD must be treated aggressively.  
11.4.9 Anemia 
Because anemia is contributing to the development of LVH in ESRD and partial correction 
of severe anemia with epoetin results in regression of LVH , epoetin treatment is advocated . 
Treatment of severe anemia is also associated with less ischemic symptoms in patient with 
CAD. However, although life quality improves after anemia correction; the evidence that 
epoetin treatment reduces cardiovascular mortality in ESRD is based on data from 
observational studies only.  
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